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Abstract: Phosphoglycosyl transferases (PGTs) represent 
“gatekeeper” enzymes in complex glycan assembly pathways by 
catalyzing transfer of a phospho-sugar from an activated nucleotide 
diphospho-sugar to a membrane-resident polyprenol phosphate. 
The unique structures of selected nucleoside antibiotics, such as 
tunicamycin and mureidomycin A, which are known to inhibit 
comparable biochemical transformations, are exploited as the 
foundation for the development of modular synthetic inhibitors of 
PGTs. Herein we present the design, synthesis and biochemical 
evaluation of two readily manipulatable modular scaffolds as 
inhibitors of monotopic bacterial PGTs. Selected compounds show 
IC50 values down to the 40 μM range, thereby serving as lead 
compounds for future development of selective and effective 
inhibitors of diverse PGTs of biological and medicinal interest.  
Introduction 
 Phosphoglycosyl transferases (PGTs), also designated as 
“priming glycosyl transferases”, act at a membrane interface and 
catalyze the transfer of C1-phosphosugars to membrane-
associated polyprenol phosphates to afford polyprenol 
diphosphosugar (Pren-PP-CHO) products. These pivotal 
intermediates then serve as acceptors for elaboration by a 
sequence of glycosyl transferases, producing highly diversified 
polyprenol diphosphate-linked glycans for glycoprotein, 
proteoglycan and glycolipid biosynthesis. Since PGTs catalyze 
the first membrane-committed step in many complex 
glycoconjugate biosynthesis pathways, they serve as 
“gatekeepers” of glycoconjugate production across all domains 
of life.[1] For example, MraY is a bacterial PGT that catalyzes 
transfer of phospho-MurNAc-pentapeptide to undecaprenol 
phosphate, mediating a key step in peptidoglycan 
biosynthesis,[2] and WecA is a bacterial phospho-GlcNAc 
transferase, which catalyzes the first step in the biosynthesis of 
lipopolysaccharide O-antigen.[3] Nucleoside antibiotics[4] that 
feature a common uridinyl motif, have been demonstrated to be 
potent inhibitors of selected PGTs, and MraY[5] and WecA[6] are 
potently inhibited by mureidomycin A and tunicamycin 
respectively (Figure 1). Recently, the importance of MraY in 
bacterial peptidoglycan synthesis has prompted major interest in 
the development of simplified nucleoside antibiotic analogues in 
the search for novel antimicrobial strategies.[7-11] 
Figure 1. Structures of mureidomycin A and tunicamycin 
PGTs also feature in eukaryotic biology, most prominently at 
the initiation of the dolichol-dependent glycosylation pathway, 
where a GlcNAc-1-phosphate transferase (GPT), designated as 
Alg7 in Saccharomyces cerevisiae and other eukaryotes, 
transfers phospho-GlcNAc to dolichol phosphate.[12] Sequence 
analysis of WecA and Alg7 reveals that these enzymes are both 
integral membrane proteins with 11 predicted transmembrane 
helices (TMHs), and that they share key predicted active site 
residues, therefore it is unsurprising that Alg7 is also potently 
inhibited by tunicamycin[13] (Figure 1).  
Unfortunately, despite the tantalizing inhibition properties 
of the uridinyl nucleoside antibiotics, their biological activities are 
hard to predict for other PGT targets, and must be empirically 
determined. This is exemplified by the large differences in 
inhibition properties of mureidomycin A and tunicamycin (Figure 
1). Furthermore, the complexity of the natural product structures 
makes it very challenging to repurpose the structures of the 
natural products, by synthesis[14-16] or semisynthesis,[17-22] to 
target alternative PGTs with different substrate specificities. This 
challenge is further exacerbated with PGTs belonging to 
structural classes other than the well-studied MraY and WecA-
type integral membrane proteins, which feature 10 and 11 
predicted TMHs respectively. For example, recent bioinformatics 
and biochemical analysis has revealed thousands of 
homologous small bacterial PGTs with only a single TMH and a 
soluble globular domain within a 20-25 kDa protein.[23] While 
these PGTs catalyze the same biochemical processes and also 
play important roles at the initiation of diverse glycoconjugate 
biosynthetic pathways, there are currently no small molecules 
inhibitors that can be used to inform on the biology and 
essentiality of particular pathways and which may ultimately 
represent novel targets for therapeutic intervention. 
A prototypic example of a small PGT is PglC from 
Campylobacter jejuni, a Gram-negative food-borne pathogen 
that is the major cause of gastroenteritis worldwide. PglC 
catalyzes the first membrane-committed step in the biosynthesis 
of virulence-associated N-linked glycoproteins in the  
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 Scheme 1. PGT reaction catalyzed by PglC 
pathogen.[24] Specifically, PglC, acting at the cytoplasmic face of 
the inner bacterial membrane, commences assembly of an 
undecaprenol-diphosphate-linked heptasaccharide, which is the 
ultimate substrate for asparagine-linked glycosylation in the 
periplasm. PglC catalyzes transfer of a modified sugar 
phosphate, di-N-acetylbacillosamine-phosphate, from the 
corresponding UDP-sugar donor, onto undecaprenyl-phosphate 
with release of UMP (Scheme 1).[25] The PGT reaction is 
isoenergetic; a diphosphate product is formed from a 
diphosphate starting material (UDP-sugar). However, it is likely 
that in nature flux through the pathway is promoted by the action 
of the subsequent glycosyl transferases, which elaborate the 
PGT product into the polyprenol diphosphate-linked glycan. 
 Currently, there is no structural information available to aid 
in the design of inhibitors towards small PGTs such as PglC. 
The only PGT that has been structurally characterized is 
MraY,[26] and the complete absence of sequence homology to 
the small PGTs reinforces that very little insight can be gleaned 
to address inhibitor development for the small PGTs from the 
MraY structure. Therefore, we have turned our attention to the 
nucleoside antibiotics as inspiration for the blueprints of new 
modular scaffolds for PGT inhibitor design. Examination of the 
structures and reported biological activities of mureidomycin A 
and tunicamycin suggests important design criteria. First the 
uridinyl moiety is a key “placeholder” for PGTs that exploit UDP-
sugar substrates and therefore this moiety should feature in 
projected inhibitors. Second, as illustrated in Figure 1, 
interception of a divalent cation-binding site, either through a 
strategic metal ion coordinating group(s) on the inhibitor (the 
tunicamycin model[1]) or by metal ion displacement with a 
protonated primary amine (the mureidomycin A model[22]) 
represents an important design feature. In this context, despite 
the diversity of PGT structures, Mg2+-dependence, presumably 
to coordinate to the uridine diphosphate to prime the substrate 
for nucleophilic attack at the β-phosphate, is common to small 
PGTs, such as PglC, as well as the multi-TMH PGTs exemplified 
by MraY, WecA and Alg7. Finally, the design should be 
compatible with extended binding determinants, including glycan, 
peptidic, and lipophilic components, to mimic the characteristics 
of the native substrates. Based on these criteria, we have 
devised two modular synthetic strategies, inspired by 
mureidomycin A and tunicamycin. Key features of both 
strategies include 1) a uridine moiety, 2) a functionality to either 
displace or coordinate to the metal ion cofactor, 3) an aromatic 
moiety that may intercept sugar binding, and, 4) a hydrophobic 
acyl moiety to either bind into the undecaprenyl-phosphate-
binding site, or potentially direct the inhibitor to the membrane 
interface. Strategy 1 (mureidomimetic) is based on 
mureidomycin A in that it includes a modification at the C5’-site 
to display three different lengths of alkylamines to explore 
placement of a positive charge adjacent to the uridine, and 
strategy 2 (tunicamimetic) is based on the incorporation of 
amino acid building blocks, once again conjugated to the uridinyl 
moiety, to explore an alternative, metal ion-coordinating 
functionality adjacent to the uridine. 
 The development of novel small PGT (e.g. PglC) inhibitors 
has also demanded attention to practical details including the 
establishment of reliable heterologous expression and 
purification procedures for the target membrane-bound 
enzyme[27] and the application of robust assays to provide 
consistent feedback on inhibitor development. One of the 
standard approaches for assaying PGTs relies on radioactivity-
based strategies that use tritium or [14C]-labeled UDP-sugars 
and undecaprenol phosphate together with liquid/liquid 
extraction of lipophilic undecaprenol-diphosphosugar products. 
For example PglC may be assayed in a coupled assay, in which 
the PglC product is further elaborated by PglA, an N-
acetylgalactosamine transferase that uses UDP-[3H]GalNAc, 
from the pgl pathway of C. jejuni.[28] In this way, tritium-labeled 
GalNAc is incorporated into the undecaprenol-diphospho-
disaccharide (Und-PP-Bac-GalNAc) and enzymatic activity is 
quantified by extraction of the hydrophobic product followed by 
scintillation counting. In order to test for PglC activity and 
inhibition directly, [3H]-labeled UDP-di-N-acetylbacillosamine 
was prepared via chemoenzymatic synthesis using [3H]-labeled 
AcCoA (Supporting Information). Since the radioactivity-based 
assays are cumbersome and labor intensive, we also present 
the use of a prototype UMP/CMP-Glo assay from Promega, 
which is a luminescent UMP detection assay, that greatly 
increased the reliability and throughput of activity and inhibition 
assays. In all cases, inhibition assays were carried out in the 
presence of 10% DMSO and 0.1% Triton X-100 in order to 
ensure that observed inhibition behavior was due to specific 
binding to the enzyme rather than promiscuous binding activity 
resulting from inhibitor aggregation effects.[29] 
Results and Discussion 
Strategy 1 – Mureidomimetics 
The first modular strategy takes its cue from mureidomycin A 
and includes a primary amine adjacent to the uridinyl moiety 
(Figure 1). Starting from free uridine, the 2’,3’-syn diol of the 
ribose was protected with an isopropylidene group, and the 5’-
hydroxyl was tosylated (Scheme 2). Substitution of the tosylate 
with mono-Boc-protected alkyldiamines (C2, C4 and C6) was 
accomplished under basic conditions after prolonged reaction 
times to yield intermediates 2-4 in good yields. Different spacer 
lengths between the uridine core and amino group were 
incorporated to investigate potential structure/function  
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Scheme 2. Synthesis of dyad inhibitors, varying alkyl length and alkyne. A) H2SO4, acetone (96%); B) p-TsCl, DMAP, DCM/pyridine (89%); C) N-Boc-alkylamine, 
K2CO3, THF (2: 78%, 3: 91%, 4: 96%); D) TFA, H2O (quant.); E) Ac-L-Ala-OH, EDC, HOBt, DMF (towards 8: 54%, 9: 37%, 10: 74%); F) i. chloroacetic anhydride, 
DCM; ii. NaN3, DMF (toward 11: quant., toward 12: 94%, toward 13: quant.); G) alkyne, CuSO4, sodium ascorbate, t-BuOH/H2O. 
dependencies in subsequent inhibition assays (vide infra). 
Removal of the N-Boc and isopropylidene protecting groups was 
accomplished simultaneously using aqueous TFA, and products 
5-7 were obtained in quantitative yield after lyophilization. Initial 
inhibition assays revealed that these first generation compounds 
5-7 inhibited PglC reaction completely at 5 mM, while activity 
was almost completely recovered at 1 mM (data not shown). 
Qualitatively, small differences were observed with the three 
congeners, so all series were forwarded for further elaboration. 
To reduce flexibility and potentially increase the opportunity 
for productive binding interactions with the enzyme, the C5’-
secondary amine position was derivatized via coupling with N-
acetyl-alanine using standard coupling conditions (EDC, HOBt). 
Although the use of the N-acetyl derivative of alanine under 
these conditions resulted in epimerization at the C-a center, the 
diasteromeric mixture was carried forward for inhibition analysis. 
While epimerization could have been prevented using the N-α-
Fmoc-protected amino acid, deprotection under basic conditions 
was known to result in decomposition of the resulting tertiary 
amide at the 5’-N in related compounds (vide infra). Acidic 
treatment to remove the isopropylidine group afforded 
compounds 8-10, which showed improved inhibition potency, 
with 78±14% inhibition at 1 mM for compound 10 (the C6-dialkyl 
amine, Figure 2A), with substrate concentrations of 20 µM UDP-
diNAcBac (KM = 7.2 ± 1.1 µM) and 20 µM Und-P (KM, app = 15.6 ±  
Figure 2. Biological evaluation of hexylamine-uridine inhibitors (A) and clicked 
product based on compound 13 (B), using the radioactivity-based activity 
assay.  Error bars indicate mean ±SD. 
5.1 µM) in the assay. At this point, it was possible to discriminate 
between the different alkyl lengths, with compound 10 being a 
superior inhibitor than 8 and 9 (see Figure S1, SI). The activity of 
compound 10 represents a significant step compared to uridine, 
which shows no inhibition of PglC at 1 mM, indicating that the 
uridine core alone is not sufficient for binding at this 
concentration (Figure 2A). In contrast, uridine monophosphate 
(UMP), which is also a side product of the PglC reaction, shows 
comparable inhibition relative to 10 at 1 mM. This is in line with 
our observations that the PglC reaction saturates at 30% 
conversion, supposedly due to UMP product inhibition. Although 
uridyl-phosphates are successfully elaborated towards potent 
glycosyl transferase inhibitors,[30-32] in the long term, the amine-
substituted derivatives would be advantageous due to the 
positive charge, which would enhance cell permeability relative 
to negatively charged analogues, as has been an inspiration in 
several inhibitor design strategies.[33-37]  
Encouraged by these initial inhibition results, the 
mureidomimetic strategy was expanded to create ‘dyad 
inhibitors’ that would display two binding modules. Instead of the 
alanine that had principally been incorporated to increase rigidity, 
a targeted screen was performed to identify a moiety that could 
potentially bind in the carbohydrate-binding site of the UDP-
sugar substrate, and therefore our attention was focused on 
mono- and bicyclic aromatic compounds that could engage in p-
stacking interactions often identified in sugar-binding sites.[38] 
The synthesis of azide-functionalized alkylamine-uridines 11-13 
involved N-acylation with chloroacetic anhydride, followed by 
chloride displacement with sodium azide in DMF and global 
deprotection under acidic conditions. Next, a selection of 
commercially available terminal alkynes (a-i, Scheme 2) was 
conjugated to 13 using standard Cu(I)/ascorbate conditions to 
catalyze the [3+2] cycloaddition click reaction. Reaction progress 
was monitored using LC-MS and purification was performed 
using SepPak C18 cartridges. For this study, the C6 compound, 
13 was used as the parent compound because the alanine-
conjugated equivalent, 10, had shown the best activity in 
inhibition assays. Indeed, a broad range of activities was  
Scheme 3. Synthesis and biological evaluation of triad inhibitors based on 
uridine-hexylamine, using the UMP/CMP-Glo assay. A) Fmoc-L-Aza-OH, EDC, 
HOBt, DMF (45%); B) immobilized piperazine, DCM; C) myristic acid, EDC, 
HOBt, DMF (48% 2 steps); D) TFA, H2O (17: 96%, 18: 85%); E) 2-ethynyl-6-
methoxynaphthalene, CuSO4, sodium ascorbate, DMF (77%). Error bars 
indicate mean ±SD. 
O
S
O O
N O
N
O
O C
N
N
a b c d
e f g h i
O
O
TsO N
NH
O
O
O
O
O
HN N
NH
O
O
O
NHBoc
n
1
2 n = 1
3 n = 3
4 n = 5
O
OH
N N
NH
O
O
OH
NH2
n
11  n = 1
12  n = 3
13  n = 5O
N3
O
OH
HN N
NH
O
O
OH
NH2
n 5 n = 1
6 n = 3
7 n = 5
O
OH
N N
NH
O
O
OH
NH2
O
AcHN
n
8 n = 1
9 n = 3
10  n = 5
O
OH
HO N
NH
O
O
OH
O
OH
N N
NH
O
O
OH
NH2
n
O
NNN 11a,f-i n = 1
12a,f-i n = 3
13a-i n = 5
A, B
F, D
E, D
C
D
G
A B 
O
OH
N N
NH
O
O
OH
O
N
H
N3
NH2
O
11
O
O
HN N
NH
O
O
O
NHBoc
O
O
N N
NH
O
O
O
O
RHN
N3
NHBoc
14  R = Fmoc
15  R = H
O
O
N N
NH
O
O
O
O
N
H
N3
NHBoc
O
11
O
OH
N N
NH
O
O
OH
O
N
H
N
NH2
O
11
N
N
OMe
1817
E, D
4
16
A
B
C
D
    
 
 
 
 
 
observed when compounds 13a-i were assayed, with 13a 
resulting in complete inhibition of PglC activity at 3 mM  (Figure 
2B). Interestingly, the parent compound 13 showed only modest 
inhibition at 3 mM, reinforcing the importance of the naphthyl 
moiety on binding. These results demonstrate the added value 
of the dyad design, and might also suggest the importance of a 
stereocenter appended to 5’-N which is lacking in 13 but present 
in 10. With the aim of distinguishing between the different spacer 
lengths at this stage of inhibitor design, we conjugated the 
alkynes that had showed the greatest inhibition potential (a, f-i) 
to the shorter parent compounds 11 and 12. Interesting trends in 
inhibition properties were observed (see Figure S2, SI), and 
although alkyne g also yielded inhibitors with improved 
properties, the overall conclusion was that inhibitor 13a, in which 
the naphthyl moiety was combined with the C6 alkylamine, 
showed the highest activity. 
Because the dyad inhibitor strategy left little opportunity for 
further functionalization, the inhibitor scaffold was modified to 
allow further derivatization toward ‘triad inhibitors’. As illustrated 
in Scheme 3, N-α-Fmoc-protected azido-alanine (Aza) was 
coupled to protected hexylamine-uridine 4, using standard 
amide coupling conditions. In this way, the scaffold has the 
potential to be modified first by click reactions at the azide 
moiety with different alkynes and second by coupling different 
carboxylic acid derivatives to the liberated amine. Ensuing Fmoc 
deprotection of compound 14 using 20% piperidine in DMF gave 
a high amount of the b-eliminated product, as well as 
decomposition back to starting compound 4 (as identified using 
LC-MS), which was inseparable from the product. While shorter 
reaction times and reduced levels of base suppressed the 
formation of the elimination product, decomposition was still 
detected. Ultimately, a systematic study of potential conditions 
resulted in the use of piperazine immobilized on polystyrene 
resin, which significantly reduced the amount of compound 4 
regenerated. Subsequently, myristic acid was coupled to the 
amine in 15, followed by acidic hydrolysis to afford inhibitor 17. 
Additionally, compound 16 was subjected to click chemistry 
conditions using 2-ethynyl-6-methoxynaphthyl to give fully 
functionalized triad inhibitor 18 after acidic hydrolysis in good 
yields. 
Inhibition assays using the UMP/CMP-Glo system revealed 
that attaching the long chain (C14) fatty acid had a positive effect 
on the inhibition potency, as exemplified by 90±3% inhibition of 
PglC at 250 µM inhibitor with substrate concentrations of 20 µM 
UDP-diNAcBac and 20 µM Und-P in the assay. The IC50 of 
compound 17 was established to be 85 ± 28 µM. This reinforces 
the importance of a hydrophobic acyl moiety in the design of 
PGT inhibitors, to either compete with the undecaprenol 
phosphate acceptor for binding, or to direct the inhibitor to the 
membrane interface proximal to where catalysis is performed. 
Interestingly, the inhibition potency decreased on going from 17 
to 18, which has the added methoxynaphthyl moiety, to 75±1% 
inhibition at 250 µM inhibitor. This corresponds to an IC50 value 
of ~ 207 µM for compound 18. This decrease in inhibition 
potency with the added naphthyl moiety is most likely explained 
by the poorer solubility of inhibitor 18 in the assay conditions. In 
addition, the exact distance between the uridine core and the 
naphthyl group is slightly longer in 18 than in the precursor 13a, 
which could indicate a slight clash in the binding site and 
therefore creating a suboptimal fit. However, it is clear from 
these results that the increasing complexity of the modular 
scaffold results in increased inhibitory potency, until an 
unfavourable interaction is introduced. Most importantly, the 
modular design of the mureidomycin mimetic strategy allows 
rapid differentiation at three positions, which will be extremely 
valuable in future optimization of this scaffold towards specific 
PGT targets. 
 
Strategy 2 - Tunicamimetics  
Having established that the combination of an alkylamine, a 
hydrophobic acyl group, and an aromatic moiety appended to a 
uridine core produced inhibitors with three points of variation, 
revealing micromolar IC50 values, we then investigated an 
alternative modular scaffold that would display similar 
functionalities, but would facilitate easier differentiation at three 
modular positions. As depicted in Scheme 4, this strategy 
started off with isopropylidene-protected 5’-amino-uridine 
(compound 19), and involved amide coupling chemistry to 
introduce the various modules. In this case, instead of a primary  
    
 
 
 
 
 
Scheme 4. Synthesis and biological evaluation of triad inhibitors based on a peptidic backbone, using the UMP/CMP-Glo assay. A) Fmoc-L-Asp(tBu)-OH, EDC, 
HOBt, DMF; B) 20% piperidine, DMF (62% 2 steps); C) Ac2O, Et3N, MeOH (24: 89%); D) TFA, H2O (21: 86% 2 steps, 25: 74% 3 steps, 26: 61% 2 steps, 28: 
quant., 29: 66%); E) Fmoc-L-Aza-OH, EDC, HOBt, DMF (71%); F) immobilized piperazine, DCM; G) myristic acid, EDC, HOBt, DMF (63% 2 steps); H) 2-ethynyl-
6-methoxynaphthalene, CuSO4, sodium ascorbate, DMF (toward 29: 93%). Error bars indicate mean ±SD. 
amine that would displace the metal in the active site, the 
strategy exploits a strategic carboxylic acid functionality to 
investigate if such compounds might offer advantages in binding 
by directly coordinating to a bound divalent cation at the active 
site.[39-40] Such a strategy would mimic the proposed effect of 
tunicamycin-like nucleosides, which are proposed to intercept 
binding as illustrated in Figure 1. To this end, Fmoc-L-Asp(tBu)-
OH was coupled to compound 19, followed by Fmoc removal 
using 20% piperidine. To generate the first generation inhibitor 
(compound 21), the free amine in 20 was capped with an acetyl, 
and the tert-butyl and isopropylidene groups were 
simultaneously removed using aqueous TFA. Next, the Aza 
building block was conjugated to allow differentiation using click 
chemistry, and compound 22 was obtained in good yield. Fmoc 
removal under mild conditions proceeded smoothly to afford 
compound 23, which was either capped with an acetyl group to 
give compound 24, or coupled with myristic acid to generate 
compound 27. The acetylated precursor 24 was either directly 
deprotected under acidic conditions to give inhibitor 25, or 
subjected to click conditions with 2-ethynyl-6-methoxynaphthyl 
to generate a new class of tunicamimetic dyad inhibitor, 26, after 
acidic hydrolysis of the protecting groups. To generate the other 
dyad inhibitor displaying the hydrophobic acyl group, myristic 
acid was coupled to compound 23 using standard amide-
coupling conditions. This resulted in compound 27, which was 
either fully deprotected using aqueous TFA to give dyad inhibitor 
28, or subjected to click conditions with 2-ethynyl-6-
methoxynaphthyl to produce the triad inhibitor 29. Because this 
second synthetic strategy was more straightforward than the first 
strategy, it allowed for thorough purification and isolation of 
intermediate compounds throughout the sequence of reactions. 
Advantageously, evaluating the inhibitory potential of the 
intermediates would provide information about the additive 
effects of the different modules on the overall potency. The 
results of the comparative inhibition assays are displayed in 
Scheme 4. Using the UMP/CMP-Glo assay, it was demonstrated 
that acid-functionalized uridine 21 inhibited PglC activity by 
57±6% at 250 µM. Notably, this inhibitory potential is 
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considerably higher than the inhibition observed with first-
generation inhibitors based on the alkylamine module (Scheme 
1, compound 7). The addition of the Aza building block did not 
influence the inhibitory potency to a great extent (25 in Scheme 
4). In contrast, the addition of either a 2-ethynyl-6-
methoxynaphthyl through click chemistry (compound 26), or a 
fatty acid moiety (compound 28) improved the inhibition of PglC, 
resulting in 77±10% and 88±5% inhibition at 250 µM respectively. 
Using the UMP/CMP-Glo assay, we were able to determine the 
IC50 values to be ~ 205 µM for 26 and 43 ± 5 µM for 28. This 
implies a modest improvement over the analogous dyad inhibitor 
17 from the first strategy. Interestingly, a similar trend in 
inhibition potential was observed with the triad inhibitor 29, 
which showed 81±3% inhibition at 250 µM, a slight decrease in 
potency compared to 28. However, this corresponded to an IC50 
of 64 ± 10 µM, which is an order of magnitude better than the 
corresponding alkylamine inhibitor 18. 
Conclusions 
The development of inhibitors for PGTs is a relatively 
unexplored field, and it holds great potential to aid our 
understanding of this important class of enzymes, and to 
generate target molecules that inhibit crucial bacterial enzymes. 
Apart from diverse nucleosides that have been targeted to inhibit 
MraY, there is little known about molecular scaffolds that inhibit 
other PGTs specifically. Bioinformatics and structural 
investigations have revealed that PGTs display highly diverse 
topologies, hinting at diverse active site architectures to catalyze 
a similar reaction. Herein, we have presented the de novo 
design of two modular scaffolds that resulted in compounds with 
low micromolar activity for PglC, the monotopic PGT that is the 
gatekeeper enzyme of N-linked glycoprotein biosynthesis in C. 
jejuni. The modular approach allowed the evaluation of adding 
different modules on the inhibitory potential of PglC. Thus, it was 
clear that, starting from uridine, the attachment of aspartate (21, 
tunicamimetic strategy) was superior to the hexylamine moiety 
(7, mureidomimetic strategy), resulting in 57% inhibition at 250 
µM with the former. Attachment of an aromatic moiety (i.e. 
naphthyl group in 26), and to a greater extent a hydrophobic 
long-chain acyl group (17 and 28) resulted in a further increase 
in inhibitory potential, while the combination of both modules 
resulted in a slight decrease (18 and 29). This detrimental effect 
might be attributed to a steric clash of the elaborated scaffold in 
the active site, or to the poor solubility of the triad inhibitors. 
Interestingly, the inhibition potentials of these scaffolds are 
similar to that of tunicamycin, which was found to have an IC50 of 
100 ± 8 µM for PglC (see Supporting Information). Together, 
these studies provide the proof-of-concept for our approach, and 
pave the way for increasing the potency and specificity for 
diverse monotpic PGTs and potentially the more complex 
polytopic PGTs by performing structure optimization at the 
diverse point of contact with the enzyme. Of paramount 
importance in these studies was the establishment of a 
reproducible enzyme purification protocol, and the development 
of a reliable activity assay, which in contrast to existing 
fluorescence-based assays for MraY, [41-42] represent a 
significant challenge. Our efforts in both of these arenas have 
greatly contributed to the generation of PglC inhibitors. In 
conclusion, the chemical and biochemical studies lay the 
foundation for a diversity-oriented approach to explore the 
chemical space allowed for inhibitors in the active site of PGTs. 
Moreover, the results will direct diversification of existing uridine 
libraries.[43-44] 
Experimental Section 
General experimental procedures. All chemicals were used as 
received unless stated otherwise. 1H and 13C NMR spectra were 
recorded on a Bruker DPX-400 (400/100 MHz), a Varian 500 (500/125 
MHz), and a Bruker AV-600 (600/150 MHz) spectrometer. Chemical 
shifts (δ) are given in ppm and coupling constants are given in Hz. All 
given 13C spectra are proton decoupled. Flash chromatography was 
performed on Silicycle Siliflash P60 silica gel (40-60μm). TLC-analysis 
was conducted on Agela Technologies TLC plates with detection by UV-
absorption (254 nm) where applicable and by spraying with 20% sulfuric 
acid in ethanol followed by charring at ~150 °C or by spraying with a 
solution of (NH4)6Mo7O24·H2O (25 g/l) and (NH4)4Ce(SO4)4·2H2O (10 g/l) 
in 10% sulfuric acid in water followed by charring at ~150 °C. LC-MS 
analysis was performed on an HP 1000 series HPLC system and 
Finnegan LCQDeca mass spectrometer. Standard eluents used were A: 
0.1% TFA in H2O, B: 0.1% TFA in acetonitrile. The column used was a 
YMC-Pack ODS-AQ column (3 μm, 100 x 3.0 mm I.D.).  All analyses 
were 15 min, with a flow-rate of 0.1 ml/min. The UMP/CMP-Glo assay 
(Promega) was used as received. Luminescent readings were performed 
on a SynergyH1 platereader (Biotek) according to protocol from Promega. 
Scintillation counting was performed on a Beckman Coulter LS6500 
scintillation counting system. 
General procedure A: Amino acid coupling. Fmoc-protected amino 
acid (2 eq) was pre-activated by mixing with EDC·HCl (2 eq) and HOBt 
(2 eq) in DMF (0.3 M) for 10 min at RT, and this mixture was added to 
the amine (1 eq). The mixture was stirred overnight, diluted with DCM 
and washed with H2O (4x). The organic fraction was dried over Na2SO4, 
concentrated in vacuo and re-dissolved in DMF (0.3 M). Piperidine (20 
vol%) was added, and the mixture was stirred until complete 
consumption of starting material was observed using LC-MS. The 
mixture was concentrated in vacuo and purified using flash column 
chromatography (silica gel, DCM/MeOH) to obtain the desired product. 
General procedure B: Click reaction in t-BuOH/H2O. The azide (2 
µmol, stock in DMSO) and alkyne (2.4 µmol, 100 mM stock in DMSO) 
were together dissolved in t-BuOH/H2O (800 µL, 1/1, v/v). CuSO4 (2 µmol, 
125 mM stock in H2O) and sodium ascorbate (4.8 µmol, 250 mM stock in 
H2O) were added and the resulting solution was incubated on a shaker at 
RT until complete consumption of the azide was observed using LC-MS 
(24-48h). The mixture was lyophilized, redissolved in H2O/MeCN and 
purified using SepPak C18 cartridges. Product fractions were lyophilized 
and redissolved in DMSO to give 50 mM stock solutions. 
General procedure C: Click reaction in DMF. A solution of the azide (1 
eq) in DMF (0.025 M) was treated with 2-ethynyl-6-methoxynaphthalene 
(4 eq), CuSO4 (1 eq, 1M stock in H2O) and sodium ascorbate (2 eq, 1M 
stock in H2O). Complete consumption of the azide was confirmed using 
LC-MS (1-3 h) and the mixture was diluted with DCM, washed with NH4Cl 
(4x), dried over Na2SO4 and concentrated in vacuo. The product was 
purified using flash column chromatography (silica gel, DCM/MeOH). 
    
 
 
 
 
 
General procedure D: Acidic hydrolysis. Protected compound (10 mg) 
was treated with TFA/H2O (500 µL, 3/2, v/v) until complete removal of the 
protecting groups was observed using LC-MS (3-24 h). The mixture was 
lyophilized repeatedly to obtain the final compound. 
Radioactivity-based activity assay with PglC. Assays contained 20 
μM Und-P, 10% DMSO, 0.1% Triton X-100, 50 mM HEPES pH 7.5, 100 
mM NaCl, 5 mM MgCl2, 20 μM [3H]-UDP-diNAcBac, and 1 nM PglC in a 
final volume of 60 μL. Inhibitors were added in DMSO, in a volume such 
that the total concentration of DMSO in the reaction was equal to 10% 
(v/v). PglC was pre-incubated in the reaction mixture lacking [3H]-UDP-
diNAcBac for five minutes at RT. After initiation of the reaction with [3H]-
UDP-diNAcBac, aliquots (20 μL) were taken at twenty minute time points 
and quenched in 1 mL CHCl3:MeOH. The organic layer was washed 
three times with 400 μL PSUP (Pure Solvent Upper Phase, composed of 
15 mL CHCl3, 240 mL MeOH, 1.83 g KCl in 235 mL H2O). The resulting 
aqueous layers were combined with 5 mL EcoLite (MP Biomedicals) 
liquid scintillation cocktail. Organic layers were combined with 5 mL 
OptiFluor (PerkinElmer). Both layers were analyzed using scintillation 
counting. The data was plotted as percentage remaining activity 
compared to the positive control (no inhibitor), and the IC50 values were 
obtained by plotting residual activity versus concentration (GraphPad 
Prism). 
Luminescence assay using UMP/CMP-Glo. The quenching solution 
was prepared as described by Promega. Assays contained 20 μM Und-P, 
10% DMSO, 0.1% Triton X-100, 50 mM HEPES pH 7.5, 100 mM NaCl, 5 
mM MgCl2, 20 μM UDP-diNAcBac, and 1 nM PglC in a final volume of 25 
μL. Inhibitors were added in DMSO, in a volume such that the total 
concentration of DMSO in the reaction was equal to 10% (v/v). PglC was 
pre-incubated in the reaction mixture lacking UDP-diNAcBac for five 
minutes at RT. After initiation of the reaction with UDP-diNAcBac, the 
reaction was halted after 20 min by the addition of 25 µL quenching 
buffer. The mixture was transferred to a 96-well plate (white, half area, 
Corning) and placed in the plate reader. The plate was shaken at low 
speed for 16 min, and incubated at RT for 44, after which time the 
luminescence was read. Background inhibition of the UMP/CMP-Glo 
assay was established for each inhibitor, and the luminescent reads were 
adjusted accordingly. 
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Biological evaluation of compounds 8-10 at 1 mM (light grey) and 500 µM (dark grey) in the PglC 
activity assay, using the radioactivity-based extraction assay. Data represented are obtained in duplicate. Error 
bars indicate mean ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Biological evaluation of clicked products based on compounds 11 (A) and 12 (B) in a PglC activity 
assay using the radioactivity-based extraction assay. Data represented are obtained in duplicate. Error bars 
indicate mean ± SD. 
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IC50 curves (generated using GraphPad Prism) 
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Experimental details 
 
2’,3’-O-isopropylidene-5’-O-(p-toluenesulfonyl)uridine (1). 2’,3’-O-isopropylidene uridine1 
(1.0 g, 3.52 mmol) was dissolved in DCM/pyridine (20 mL, 3/1, v/v) under a nitrogen 
atmosphere. p-Toluenesulfonyl chloride (1.34 g, 7.04 mmol) and 4-dimethylaminopyridine (43 
mg, 0.35 mmol) were added, and the resulting solution was stirred at RT for 24 h. The reaction 
was quenched by the addition of methanol (2 mL), diluted with DCM and washed with sat. aq. 
NaHCO3 and brine. The organic layer was dried over Na2SO4, concentrated and the title 
compound was isolated after flash column chromatography (silica gel, 33% hexane in EtOAc) 
as a colorless foam (Yield: 1.37 g, 3.12 mmol, 89%). The analytical data were in accord with those previously 
reported.2 
 
 
5’-N-(tert-butyl N-[2-aminoethyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene 
uridine (2). Tosyl uridine 1 (200 mg, 0.46 mmol) was dissolved in dry THF (2 mL) and treated 
with N-Boc-ethylenediamine (0.14 mL, 0.91 mmol) and K2CO3 (0.13 g, 0.91 mmol). The 
resulting suspension was stirred for 7 days, after which time the mixture was diluted with DCM 
and washed with H2O (2x). The organic layer was dried over Na2SO4, concentrated in vacuo 
and purified using flash column chromatography (silica gel, 10% MeOH in DCM) to afford the 
title compound as a colorless foam (Yield: 151 mg, 0.35 mmol, 78%). TLC: Rf = 0.38 (DCM/MeOH, 9/1, v/v); 
1H NMR (CDCl3, 400 MHz): δ 7.21 (d, 1H, J = 7.4 Hz, H-6) 7.05 (s, 1H, NH), 5.72 (d, 1H, J = 7.6 Hz, H-5), 
5.56 (s, 1H, NH), 5.19 (d, 1H, J = 3.9 Hz, H-1’), 4.95 (dd, 1H, J = 1.8, 6.5 Hz, H-3’), 4.90 (dd, 1H, J = 4.6, 6.4 
Hz, H-2’), 4.28 (d, 1H, J = 1.3 Hz, H-4’), 3.90 (dd, 1H, J = 1.8, 12.2 Hz, H-5’), 3.85 (d, 1H, J = 11.4 Hz, H-5’), 
3.42 – 3.55 (m, 2H, CH2), 3.20 – 3.33 (m, 2H, CH2), 1.52 (s, 3H, CH3 iPr), 1.32 (s, 9H, CH3 tBu), 1.29 (s, 3H, 
CH3 iPr); 13C NMR (CDCl3, 100 MHz): δ 171.9 (C=O Boc), 156.7 (C-4), 153.2 (C-2), 141.1 (C-6), 114.9 (Cq 
iPr), 106.0 (C-5), 99.0 (C-1’), 85.6 (C-4’), 81.9, 80.7 (C-2’, C-3’), 79.3 (Cq tBu), 61.0 (C-5’), 41.1, 39.9 (CH2), 
28.4 (CH3 tBu), 27.3, 25.2 (CH3 iPr); LC: Rt = 6.36 min; ESI-MS: m/z = 427.13 (M+H+).  
 
 
5’-N-(tert-butyl N-[4-aminobutyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene 
uridine (3). Tosyl uridine 1 (110 mg, 0.25 mmol) was dissolved in dry THF (2 mL) and 
treated with N-Boc-1,4-butanediamine (94 mg, 0.50 mmol) and K2CO3 (138 mg, 1.0 mmol). 
The resulting suspension was stirred for 3 days, after which time the mixture was diluted with 
DCM and washed with H2O (2x). The organic layer was dried over Na2SO4, concentrated in 
vacuo and purified using flash column chromatography (silica gel, 8% MeOH in DCM) to 
afford the title compound as a colorless oil (Yield: 103 mg, 0.23 mmol, 91%). TLC: Rf = 0.37 
(DCM/MeOH, 9/1, v/v); 1H NMR (CDCl3, 400 MHz): δ 7.18 (d, 1H, J = 7.7 Hz, H-6), 7.12 (t, 1H, J = 4.6 Hz, 
NH), 6.31 (bs, 1H, NH), 5.75 (d, 1H, J = 7.6 Hz, H-5), 5.30 (t, 1H, J = 5.0 Hz, NH), 5.17 (d, 1H, J = 4.8 Hz, H-
1’), 4.97 (dd, 1H, J = 1.9, 6.6 Hz, H-3’), 4.92 (dd, 1H, J = 5.0, 6.4 Hz, H-2’), 4.30 (s, 1H, H-4’), 3.92 (d, 1H, J = 
11.7 Hz, H-5’), 3.88 (dd, 1H, J = 1.3, 11.8 Hz, H-5’), 3.31 – 3.38 (m, 2H, CH2), 2.98 – 3.07 (m, 2H, CH2), 1.53 
– 1.62 (m, 2H, CH2), 1.54 (s, 3H, CH3 iPr), 1.38 – 1.47 (m, 2H, CH2), 1.38 (s, 9H, CH3 tBu), 1.30 (s, 3H, CH3 
iPr); 13C NMR (CDCl3, 100 MHz): δ 172.0 (C=O Boc), 156.5 (C-4), 152.9 (C-2), 141.3 (C-6), 114.9 (Cq iPr), 
105.9 (C-5), 99.5 (C-1’), 85.2 (C-4’), 81.2, 80.7 (C-2’, C-3’), 79.2 (Cq tBu), 60.9 (C-5’), 40.8, 40.0 (CH2), 28.4 
(CH3 tBu), 27.3 (CH3 iPr), 27.2, 25.8 (CH2), 25.1 (CH3 iPr); LC: Rt = 6.65 min; ESI-MS: m/z = 455.13 (M+H+).  
 
 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 A. M. Bello, E. Poduch, M. Fujihashi, M. Amani, Y. Li, I. Crandall, R. Hui, P. I. Lee, K. C. Kain, E. F. Pai, L. P. Kotra, J. 
Med. Chem. 2007, 50, 915-921. 
2 H. J. Korhonen, H. L. Bolt, D. R. W. Hodgson, Beilstein J. Org. Chem. 2015, 11, 469-472. 
O
O
HN N
NH
O
O
O
NHBoc
O
O
HN N
NH
O
O
O
NHBoc
O
O
TsO N
NH
O
O
O
 5 
5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-
isopropylidene uridine (4). Tosyl uridine 1 (200 mg, 0.46 mmol) was dissolved in dry 
THF (2 mL) and treated with N-Boc-1,6-hexanediamine (230 mg, 0.91 mmol) and K2CO3 
(378 mg, 2.74 mmol). The resulting suspension was stirred for 7 days, after which time the 
mixture was diluted with DCM and washed with H2O (2x). The organic layer was dried 
over Na2SO4, concentrated in vacuo and purified using flash column chromatography (silica 
gel, 8% MeOH in DCM) to afford the title compound as a colorless oil (Yield: 210 mg, 
0.44 mmol, 96%). TLC: Rf = 0.46 (DCM/MeOH, 9/1, v/v); 1H NMR (CDCl3, 400 MHz): δ 
7.27 (d, 1H, J = 7.8 Hz, H-6), 6.76 (t, 1H, J = 4.8 Hz, NH), 6.81 (t, 1H, J = 4.6 Hz, NH), 6.33 (bs, 1H, NH), 5.69 
(d, 1H, J = 7.6 Hz, H-5), 5.18 (d, 1H, J = 4.8 Hz, H-1’), 4.97 (bs, 1H, NH), 4.95 (dd, 1H, J = 1.8, 6.4 Hz, H-3’), 
4.85 (dd, 1H, J = 5.1, 6.0 Hz, H-2’), 4.31 (d, 1H, J = 1.3 Hz, H-4’), 3.87 (s, 2H, H-5’), 3.22 – 3.38 (m, 2H, 
CH2), 2.94 – 3.02 (m, 2H, CH2), 1.52 (s, 3H, CH3 iPr), 1.46 – 1.54 (m, 2H, CH2), 1.35 (s, 9H, CH3 tBu), 1.32 – 
1.40 (m, 2H, CH2), 1.28 (s, 3H, CH3 iPr), 1.18 – 1.25 (m, 4H, CH2); 13C NMR (CDCl3, 100 MHz): δ 172.1 
(C=O Boc), 156.2 (C-4), 152.9 (C-2), 140.6 (C-6), 114.7 (Cq iPr), 105.6 (C-5), 98.7 (C-1’), 85.6 (C-4’), 81.9, 
81.1 (C-2’, C-3’), 79.0 (Cq tBu), 61.1 (C-5’), 41.5, 40.4, 29.7, 28.5 (CH2), 28.4 (CH3 tBu), 27.3 (CH3 iPr), 26.4, 
26.2 (CH2), 25.2 (CH3 iPr); LC: Rt = 7.48 min; ESI-MS: m/z = 483.20 (M+H+). 
 
 
5’-N-(2-aminoethyl)-5’-amino-5’-deoxy-uridine (5). The title compound was obtained from 
compound 2 (43 mg, 0.10 mmol) using general procedure D (Yield: 28 mg, 0.10 mmol, quant.). 
1H NMR (D2O, 400 MHz) δ 8.11 (d, 1H, J = 7.7 Hz, H-6), 6.28 (d, 1H, J = 7.7 Hz, H-5), 5.64 
(d, 1H, J = 6.0 Hz, H-1’), 4.44 (dd, 1H, J = 6.1, 5.0 Hz, H-2’), 4.15 – 4.24 (m, 2H, H-3’, H-4’), 
3.65 – 3.84 (m, 4H, H-5’, CH2), 3.20 (t, 2H, J = 5.9 Hz, CH2); 13C NMR (D2O, 100 MHz): δ 
170.7 (C-4), 153.9 (C-2), 144.6 (C-6), 102.1 (C-5), 93.1 (C-1’), 86.7 (C4’), 73.1 (C-2’), 70.0 
(C-3’), 60.5 (C-5’), 39.3, 38.4 (CH2). 
 
 
5’-N-(4-aminobutyl)-5’-amino-5’-deoxy-uridine (6). The title compound was obtained from 
compound 3 (53 mg, 0.12 mmol) using general procedure D (Yield: 36 mg, 0.12 mmol, 
quant.). 1H NMR (D2O, 400 MHz) δ 7.91 (d, 1H, J = 8.1 Hz, H-6), 6.08 (d, 1H, J = 8.0 Hz, H-
5), 5.59 (d, 1H, J = 6.4 Hz, H-1’), 4.42 (dd, 1H, J = 6.4, 5.3 Hz, H-2’), 4.17 – 4.25 (m, 2H, H-
3’, H-4’), 3.78 (ddd, J = 2.8, 12.5 Hz, H-5’), 3.72 (dd, 1H, J = 3.1, 12.7 Hz, H-5’), 3.42 – 3.48 
(m, 2H, CH2), 2.90 – 2.96 (m, 2H, CH2), 1.60 – 1.70 (m, 4H, CH2); 13C NMR (D2O, 100 
MHz) δ 164.2 (C-4), 151.4 (C-2), 143.1 (C-6), 103.8 (C-5), 93.5 (C-1’), 87.0 (C-4’), 72.9 (C-
2’), 70.2 (C-3’), 60.5 (C-5’), 41.9, 38.9, 24.5, 23.9 (CH2). 
 
 
5’-N-(6-aminohexyl)-5’-amino-5’-deoxy-uridine (7). The title compound was obtained 
from compound 4 (63 mg, 0.13 mmol) using general procedure D (Yield: 44 mg, 0.13 
mmol, quant.). 1H NMR (D2O, 400 MHz) δ 7.86 (dd, 1H, J = 3.9, 8.2 Hz, H-6), 6.02 (dd, 
1H, J = 4.3, 8.1 Hz, H-5), 5.55 (dd, 1H, J = 4.2, 6.5 Hz, H-1’), 4.35 – 4.44 (m, 1H, H-2’), 
4.13 – 4.23 (m, 2H, H-3’, H-4’), 3.68 – 3.79 (m, 2H, H-5’), 3.32 – 3.42 (m, 2H, CH2), 2.82 
– 2.89 (m, 2H, CH2), 1.48 – 1.60 (m, 4H, CH2), 1.23 – 1.32 (m, 4H, CH2); 13C NMR (D2O, 
100 MHz) δ 163.1 (C-4), 150.9 (C-2), 142.9 (C-6), 103.9 (C-5), 93.7 (C-1’), 87.1 (C-4’), 
72.8 (C-2’), 70.3 (C-3’), 60.5 (C-5’), 42.8, 39.3, 27.1, 26.8, 25.3, 25.1 (CH2). 
 
 
5’-N-(N-acetyl-D/L-alanine)-5’-N-(tert-butyl N-[2-aminoethyl] carbamate)-5’-amino-
5’-deoxy-2’,3’-O-isopropylidene uridine (30). Ac-L-Ala-OH (81 mg, 0.62 mmol) in 
DMF (300 µL) was pre-activated with EDC·HCl (119 mg, 0.62 mmol) and HOBt (95 
mg, 0.62 mmol) for 15 min at RT, followed by addition of the mixture to compound 2 
(88 mg, 0.21 mmol) in DMF (200 µL). The resulting mixture was stirred for 6 days, after 
which time the mixture was diluted with DCM, washed with H2O (4x), dried over 
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Na2SO4 and concentrated in vacuo. Flash column purification (silica gel, 15% MeOH in DCM) yielded the title 
compound as a colorless oil (Yield: 60 mg, 0.11 mmol, 54%). Due to epimerization and rotamerization, the 1H 
and 13C spectra were difficult to interpret. Based on the purity by LC-MS, compound 30 was used in the next 
step, and fully characterized thereafter. TLC: Rf = 0.40 (DCM/MeOH, 9/1, v/v); LC: Rt = 6.78 min; ESI-MS: 
m/z = 540.27 (M+H+). 
 
 
5’-N-(N-acetyl-D/L-alanine)-5’-N-(2-aminoethyl)-5’-amino-5’-deoxy-uridine (8). 
Compound 30 (23 mg, 43 µmol) was deprotected using general procedure D to give the 
product as white solids (Yield: 16.7 mg, 42 µmol, quant., A : B = 0.3 : 1). 1H NMR (D2O, 
600 MHz) δ 8.02 (d, 0.3H, J = 7.7 Hz, H-6A), 7.94 (dd, 1H, J = 4.8, 7.7 Hz, H-6B), 6.14 – 
6.22 (m, 1.3H, H-5A, H-5B), 5.61 (dd, 1H, J = 1.9, 5.8 Hz, H-1’B), 5.53 (d, 0.3H, J = 6.3 
Hz, H-1’A), 4.20 – 4.36 (m, 4.3H, H-2’A, H-2’B, H-4’B, H-5’B), 4.05 – 4.18 (m, 2.9H, H-3’A, H-3’B, H-4’A, CH-
AlaA, CH-AlaB), 3.62 – 3.68 (m, 3.2H, H-5’A, CH2), 3.09 – 3.13 (m, 2.6H, CH2), 1.83 (s, 0.9H, CH3 NHAc-A), 
1.80 (s, 3H, CH3 NHAc-B), 1.19 – 1.24 (m, 3H, CH3-AlaB), 1.13 – 1.18 (m, 0.9H, CH3-AlaA); 13C NMR (D2O, 
150 MHz) δ 174.2, 174.1, 173.9, 173.8 (C=O), 171.1 (C-4B), 170.9 (C-4A), 154.2 (C-2B), 154.0 (C-2A), 144.4 
(C-6A), 142.5 (C-6B), 102.7 (C-5B), 102.3 (C-5A), 93.0 (C-1’A), 91.1 (C-1’B), 86.6 (C-4’A), 83.7 (C-4’B), 74.3 (C-
2’B), 73.0 (C-2’A), 70.2 (C-3’B), 70.0 (C-3’A), 64.3 (C-5’B), 60.5 (C-5’A), 48.8 (CH-AlaB), 48.6 (CH-AlaA), 39.3, 
39.2, 38.5 (CH2), 21.4, 21.3 (CH3 NHAc), 16.0, 15.7 (CH3 Ala); LC: Rt = 1.96 min; ESI-MS: m/z = 400.27 
(M+H+). 
 
 
5’-N-(N-acetyl-D/L-alanine)-5’-N-(tert-butyl N-[4-aminobutyl] carbamate)-5’-amino-
5’-deoxy-2’,3’-O-isopropylidene uridine (31). Ac-L-Ala-OH (74 mg, 0.56 mmol) in 
DMF (300 µL) was pre-activated with EDC·HCl (109 mg, 0.56 mmol) and HOBt (87 mg, 
0.56 mmol) for 15 min at RT, followed by addition of the mixture to compound 3 (86 mg, 
0.19 mmol) in DMF (200 µL). The resulting mixture was stirred for 6 days, after which 
time the mixture was diluted with DCM, washed with H2O (4x), dried over Na2SO4 and 
concentrated in vacuo. Flash column purification (silica gel, 8% MeOH in DCM) yielded 
the title compound as a colorless oil (40 mg, 70.5 µmol, 37%). Due to epimerization and 
rotamerization, the 1H and 13C spectra were difficult to interpret. Based on the purity by LC-MS, compound 31 
was used in the next step, and fully characterized thereafter. TLC: Rf = 0.34 (DCM/MeOH, 9/1, v/v); LC: Rt = 
6.71, 6.78 min; ESI-MS: m/z = 590.70 (M+Na+). 
 
 
5’-N-(N-acetyl-D/L-alanine)-5’-N-(4-aminobutyl)-5’-amino-5’-deoxy-uridine (9). 
Compound 31 (14 mg, 24 µmol) was deprotected using general procedure D to give the 
product as white solids (Yield: 9.7 mg, 23 µmol, quant., A : B = 1 : 0.14). 1H NMR (D2O, 
600 MHz) major species: δ 7.87 (dd, 1H, J = 8.1, 9.8 Hz, H-6), 6.11 (d, 1H, J = 8.1 Hz, 
H-5), 5.66 (dd, 1H, J = 1.9, 5.9 Hz, H-1’), 4.38 – 4.42 (m, 2H, H-2’, H-3’), 4.36 (q, 1H, J 
= 4.36 Hz, CH Ala), 4.26 – 4.32 (m, 1H, H-4’), 4.18 – 4.24 (m, 2H, H-5’), 3.41 – 3.48 (m, 
2H, CH2), 2.89 (m, 2.94 (m, 2H, CH2), 1.87 (s, 3H, CH3 NHAc), 1.60 – 1.69 (m, 4H, CH2), 1.26 (t, 3H, J = 7.4 
Hz, CH3 Ala); 13C NMR (D2O, 150 MHz) major species: δ 174.2, 173.9 (C=O), 164.4 (C-4), 151.8 (C-2), 141.0 
(C-6), 104.0 (C-5), 91.3 (C-1’), 84.2 (C-4’), 74.4 (C-2’), 70.3 (C-3’), 64.4 (C-5’), 48.8 (CH Ala), 42.0, 38.9, 
24.5, 23.9 (CH2), 21.3 (CH3 NHAc), 15.7 (CH3 Ala); LC: Rt = 1.65 min; ESI-MS: m/z = 450.33 (M+Na+). 
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5’-N-(N-acetyl-D/L-alanine)-5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-5’-
amino-5’-deoxy-2’,3’-O-isopropylidene uridine (32). Ac-L-Ala-OH (72 mg, 0.55 
mmol) in DMF (300 µL) was pre-activated with EDC·HCl (86 mg, 0.55 mmol) and 
HOBt (69 mg, 0.55 mmol) for 15 min at RT, followed by addition of the mixture to 
compound 4 (72 mg, 0.15 mmol) in DMF (200 µL). The resulting mixture was stirred 
for 6 days, after which time the mixture was diluted with DCM, washed with H2O (4x), 
dried over Na2SO4 and concentrated in vacuo. Flash column purification (silica gel, 10% 
MeOH in DCM) yielded the title compound as a colorless oil (Yield: 66 mg, 0.11 mmol, 
74%). Due to epimerization and rotamerization, the 1H and 13C spectra were difficult to 
interpret. Based on the purity by LC-MS, compound 32 was used in the next step, and fully characterized 
thereafter. TLC: Rf = 0.34 (DCM/MeOH, 9/1, v/v); LC: Rt = 7.36, 7.43 min; ESI-MS: m/z = 618.33 (M+Na+). 
 
 
5’-N-(N-acetyl-D/L-alanine)-5’-N-(6-aminohexyl)-5’-amino-5’-deoxy- uridine 
(10). Compound 32 (16 mg, 27 µmol) was deprotected using general procedure D to 
give the product as white solids (Yield: 12.3 mg, 27 µmol, quant., A : B = 1 : 0.13). 
1H NMR (D2O, 600 MHz) major species: δ 7.84 (dd, 1H, J = 8.2, 9.6 Hz, H-6), 6.07 
(d, 1H, J = 8.1 Hz, H-5), 5.65 (dd, 1H, J = 2.2, 5.8 Hz, H-1’), 4.37 – 4.44 (m, 2H, H-
2’, H-3’), 4.34 – 4.37 (m, 1H, CH Ala), 4.26 – 4.31 (m, 1H, H-5’), 4.18 – 4.24 (m, 
3H, H-4’, H-5’), 3.37 – 4.43 (m, 2H, CH2), 2.84 – 2.89 (m, 2H, CH2), 1.87 (s, 3H, 
CH3 NHAc), 1.52 – 1.63 (m, 4H, CH2), 1.23 – 1.34 (m, 7H, CH2, CH3 Ala); 13C NMR 
(D2O, 150 MHz) major species: δ 174.2, 173.9 (C=O), 163.3 (C-4), 151.3 (C-2), 140.7 (C-6), 104.3 (C-5), 91.4 
(C-1’), 84.3 (C-4’), 74.4 (C-2’), 70.4 (C-3’), 64.4 (C-5’), 48.8 (CH Ala), 42.7, 39.3, 27.1, 26.5, 25.2, 25.2 (CH2), 
21.3 (CH3 NHAc), 15.7 (CH3 Ala); LC: Rt = 1.80 min; ESI-MS: m/z = 456.40 (M+H+). 
 
 
5’-N-azidoacetyl-5’-N-(tert-butyl N-[2-aminoethyl] carbamate)-5’-amino-5’-deoxy-
2’,3’-O-isopropylidene uridine (33). Compound 2 (40 mg, 94 µmol) was dissolved in 
dry DMF (800 µL) and treated with chloroacetic anhydride (32 mg, 187 µmol) and 
pyridine (15 µL, 187 µmol) for 20 min at RT. The mixture was diluted with DCM and 
quenched by the addition of aq. NaHCO3. The organic layer was separated, dried over 
Na2SO4 and concentrated in vacuo. The intermediate was re-dissolved in DMF (800 µL) 
and treated with NaN3 overnight at RT. The mixture was diluted with DCM and washed with sat. aq. NaCl. The 
organic layer was dried over Na2SO4, concentrated in vacuo, and the product was purified using flash column 
chromatography (silica gel, 5% MeOH in DCM) (Yield: 48 mg, 93 µmol, quant.). 1H NMR (CDCl3, 400 MHz) 
δ 7.37 (d, 1H, J = 7.8 Hz, H-6), 5.91 (d, 1H, J = 7.5 Hz, H-5), 5.59 (d, 1H, J = 3.9 Hz, H-1’), 5.52 (bs, 1H, NH), 
4.89 (dd, 1H, J = 4.0, 6.7 Hz, H-3’), 4.81 (dd, J = 6.7, 2.7 Hz, H-2’), 4.48 – 455 (m, 3H, H-4’, H-5’), 3.99 (s, 
2H, CH2-N3), 3.45 – 3.62 (m, 2H, CH2), 3.25 – 3.44 (m, 2H, CH2), 1.65 (s, 3H, CH3 iPr), 1.43 (s, 9H, CH3 tBu), 
1.40 (s, 3H, CH3 iPr); 13C NMR (CDCl3, 100 MHz) δ 167.9 (C=O), 93.8 (C-1’), 83.7 (C-4’), 82.5, 80.4 (C-2’, C-
3’), 79.5 (Cq tBu), 64.4 (C-5’), 50.3 (CH2-N3), 28.4 (CH3 tBu), 27.0, 25.3 (CH3 iPr);	  LC: Rt = 8.11 min; ESI-
MS: m/z = 510.20 (M+H+). 
 
 
5’-N-azidoacetyl-5’-N-(2-aminoethyl)-5’-amino-5’-deoxy-uridine (11). Compound 
33 (48 mg, 93 µmol) was deprotected using general procedure D to give the product as 
a colorless oil (Yield: 34 mg, 93 µmol, quant.). 1H NMR (DMSO-d6, 500 MHz): δ 8.02 
(d, 1H, J = 7.7 Hz, H-6), 5.92 (d, 1H, J = 7.8 Hz, H-5), 5.58 (d, 1H, J = 5.8 Hz, H-1’), 
4.68 (d, 1H, J = 5.3 Hz, H-2’), 4.15 – 4.20 (m, 2H, H-3’, H-4’), 3.95 – 4.00 (m, 2H, H-
5’), 3.97 (s, 2H, CH2-N3), 3.47 – 3.52 (m, 2H, CH2), 2.94 – 3.05 (m, 2H, CH2); 13C 
NMR (DMSO-d6, 125 MHz): δ 171.2 (C=O), 169.7 (C-4), 155.9 (C-2), 142.5 (C-6), 
105.2 (C-5), 95.6 (C-1’), 87.4 (C-4’), 74.7 (C-2’), 70.9 (C-3’), 61.6 (C-5’), 50.6 (CH2-N3), 39.5, 39.4 (CH2); LC: 
Rt = 3.09 min; ESI-MS: m/z = 370.13 (M+H+).  
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5’-N-azidoacetyl-5’-N-(tert-butyl N-[4-aminobutyl] carbamate)-5’-amino-5’-
deoxy-2’,3’-O-isopropylidene uridine (34). Compound 3 (87 mg, 192 µmol) was 
dissolved in dry DMF (800 µL) and treated with chloroacetic anhydride (65 mg, 383 
µmol) and pyridine (31µL, 383 µmol) for 20 min at RT. The mixture was diluted with 
DCM and quenched by the addition of aq. NaHCO3. The organic layer was separated, 
dried over Na2SO4 and concentrated in vacuo. The intermediate was re-dissolved in 
DMF (800 µL) and treated with NaN3 (37 mg, 569 µmol) overnight at RT. The mixture 
was diluted with DCM and washed with sat. aq. NaCl. The organic layer was dried 
over Na2SO4, concentrated in vacuo, and the product was purified using flash column 
chromatography (silica gel, 5% MeOH in DCM) (Yield: 97 mg, 181 µmol, 94%). 1H NMR (CDCl3, 400 MHz): 
δ 7.35 (d, 1H, J = 3.9 Hz, H-6), 5.55 – 5.59 (m, 2H, H-5, NH), 5.53 (d, 1H, J = 3.9 Hz, H-1’), 4.55 – 4.58 (m, 
3H, H-2’, H-3’, NH), 4.48 – 4.52 (m, 3H, H-4’, H-5’), 3.94 (s, 2H, CH2-N3), 3.40 – 3.48 (m, 2H, CH2), 3.05 – 
3.15 (m, 2H, CH2), 1.56 – 1.63 (m, 5H, CH2, CH3 iPr), 1.50 – 1.56 (m, 2H, CH2), 1.41 (s, 9H, CH3 tBu), 1.38 (s, 
3H, CH3 iPr); 13C NMR (CDCl3, 100 MHz): δ 167.8, 156.1 (C=O), 136.2 (C-6), 116.2 (Cq iPr), 106.3 (C-5), 
93.6 (C-1’), 84.0 (C-4’), 82.5, 80.8 (C’-2, C-3’), 79.0 (Cq tBu), 64.5 (C-5’), 50.3 (CH2-N3), 41.8, 40.1 (CH2), 
28.4 (CH3 tBu), 27.5 (CH2), 27.0 (CH3 iPr), 26.1 (CH2), 25.2 (CH3 iPr); LC: Rt = 7.93 min; ESI-MS: m/z = 
538.13 (M+H+). 
 
 
5’-N-azidoacetyl-5’-N-(4-aminobutyl)-5’-amino-5’-deoxy-uridine (12). Compound 
34 (79 mg, 148 µmol) was deprotected using general procedure D to give the product 
as a colorless oil (Yield: 57 mg, 146 µmol, quant.). 1H NMR (DMSO-d6, 500 MHz): δ 
8.06 (d, 1H, J = 7.8 Hz, H-6), 6.02 (d, 1H, J = 7.7 Hz, H-5), 5.57 (d, 1H, J = 6.4 Hz, H-
1’), 4.68 (d, 1H, J = 5.3 Hz, H-2’), 4.16 – 4.20 (m, 1H, H-3’), 4.01 – 4.04 (m, 1H, H-
4’), 3.97 (s, 2H, CH2-N3), 3.62 – 3.66 (m, 2H, H-5’), 3.27 – 3.33 (m, 2H, CH2), 2.75 – 
2.85 (m, 2H, CH2), 1.50 – 1.58 (m, 4H, CH2); 13C NMR (DMSO-d6, 125 MHz): δ 
171.2 (C=O), 169.6 (C-4), 153.6 (C-2), 144.4 (C-6), 104.1 (C-5), 94.0 (C-1’), 87.9 (C-
4’), 73.9 (C-2’), 71.1 (C-3’), 61.7 (C-5’), 50.6 (CH2-N3), 41.4, 39.6, 26.4, 25.4 (CH2); LC: Rt = 2.32 min; ESI-
MS: m/z = 398.20 (M+H+). 
 
 
5’-N-azidoacetyl-5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-5’-amino-5’-
deoxy-2’,3’-O-isopropylidene uridine (35). Compound 4 (112 mg, 232 µmol) was 
dissolved in dry DMF (1 mL) and treated with chloroacetic anhydride (80 mg, 464 
µmol) and pyridine (37 µL, 464 µmol) for 20 min at RT. The mixture was diluted with 
DCM and quenched by the addition of aq. NaHCO3. The organic layer was separated, 
dried over Na2SO4 and concentrated in vacuo. The intermediate was re-dissolved in 
DMF (1 mL) and treated with NaN3 (45 mg, 692 µmol) overnight at RT. The mixture 
was diluted with DCM and washed with sat. aq. NaCl. The organic layer was dried 
over Na2SO4, concentrated in vacuo, and the product was purified using flash column 
chromatography (silica gel, 5% MeOH in DCM) (Yield: 129 mg, 230 µmol, quant.). 1H 
NMR (CDCl3, 400 MHz): δ 7.23 – 7.30 (m, 1H, H-6), 5.74 (d, J = 7.7 Hz, H-5), 5.66 (bs, 1H, NH), 5.43 (d, 1H, 
J = 4.0 Hz, H-1’), 4.83 (bs, 1H, NH), 4.72 – 4.77 (m, 1H, H-3’), 4.66 – 4.72 (m, 1H, H-2’), 4.45 – 4.50 (m, 1H, 
H-4’), 4.32 – 4.44 (m, 2H, H-5’), 3.87 (s, 2H, CH2-N3), 3.29 – 3.38 (m, 2H, CH2), 2.93 – 3.05 (m, 2H, CH2), 
1.44 – 1.55 (m, 5H, CH2, CH3 iPr), 1.20 – 1.40 (m, 18H, CH2, CH3 iPr, CH3 tBu); 13C NMR (CDCl3, 100 MHz): 
δ 167.8, 156.0 (C=O), 135.9 (C-6), 115.8 (Cq iPr), 106.4 (C-5), 93.4 (C-1’), 84.0 (C-4’), 82.4, 80.8 (C-2’, C-3’), 
78.7 (Cq tBu), 64.5 (C-5’), 50.2 (CH2-N3), 41.8, 40.2, 29.9, 28.7 (CH2), 28.3 (CH3 tBu), 27.0 (CH3 iPr), 26.3, 
26.2 (CH2), 25.1 (CH3 iPr); LC: Rt = 9.49 min; ESI-MS: m/z = 565.33 (M+H+). 
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5’-N-azidoacetyl-5’-N-(6-aminohexyl)-5’-amino-5’-deoxy-uridine (13). Compound 
35 (119 mg, 211 µmol) was deprotected using general procedure D to give the product 
as a colorless oil (Yield: 89 mg, 208 µmol, quant.). 1H NMR (DMSO-d6, 500 MHz): δ 
8.15 (d, 1H, J = 7.7 Hz, H-6), 6.11 (d, 1H, J = 7.6 Hz, H-5), 5.62 (d, 1H, J = 6.3 Hz, H-
1’), 4.20 – 4.23 (m, 1H, H-2’), 4.02 – 4.05 (m, 2H, H-3’, H-4’), 3.97 (s, 2H, CH2-N3), 
3.64 (d, 2H, J = 2.4 Hz, H-5’), 3.30 – 3.40 (m, 2H, CH2), 2.70 – 2.80 (m, 2H, CH2), 
1.47 – 1.55 (m, 4H, CH2), 1.24 – 1.35 (m, 4H, CH2); 13C NMR (DMSO-d6, 125 MHz): 
δ 171.2 (C=O), 169.5 (C-4), 153.5 (C-2), 145.2 (C-6), 103.3 (C-5), 94.3 (C-1’), 88.2 
(C-4’), 74.0 (C-2’), 71.1 (C-3’), 61.6 (C-5’), 50.6 (CH2-N3), 42.6, 39.9, 29.0, 28.0, 26.7, 
26.5 (CH2); LC: Rt = 1.64 min; ESI-MS: m/z = 425.47 (M+H+). 
 
 
5’-N-(N-[9-fluorenylmethoxycarbonyl]-3-azido-L-alanine)-5’-N-(tert-butyl N-[6-
aminohexyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine (14). 
Fmoc-L-Aza-OH (119 mg, 338 µmol) was dissolved in DMF (250 µL) and pre-
activated by the addition of EDC·HCl (69 mg, 360 µmol) and HOBt (55 mg, 360 
µmol) and the solution was stirred for 10 min at RT. The mixture was subsequently 
added to a solution of compound 4 in DMF (200 µL), and the resulting solution was 
stirred overnight. The mixture was diluted with DCM and washed with H2O (4x), 
dried over Na2SO4 and concentrated in vacuo. Flash column chromatography (silica 
gel, 4% MeOH in DCM) afforded the pure title compound as a colorless oil (Yield: 82 mg, 101 µmol, 45%). 
TLC: Rf = 0.53 (DCM/MeOH, 9/1, v/v); 1H NMR (CDCl3, 400 MHz): δ 7.67 (d, 2H, J = 7.6 Hz, CHarom), 7.51 
(d, 2H, J = 7.4 Hz, CHarom), 7.31 (t, 3H, J = 7.9 Hz, CHarom, H-6), 7.18 – 7.25 (m, 2H, CHarom), 6.28 (d, 1H, J = 
6.0 Hz, NH), 5.79 (d, 1H, J = 7.3 Hz, H-5), 5.35 (bs, 1H, NH), 5.24 (d, 1H, J = 3.5 Hz, H-1’), 4.64 – 4.75 (m, 
2H, H-2’, H-3’), 4.34 – 4.49 (m, 4H, H-4’, CH2 Fmoc, CHH Aza), 4.25 – 4.32 (m, 2H, CH Aza, CHH Aza), 
4.12 (t, 1H, J = 6.9 Hz, CH Fmoc), 3.64 – 3.75 (m, 2H, H-5’), 3.25 – 3.37 (m, 2H, CH2), 2.94 – 3.03 (m, 2H, 
CH2), 1.52 (s, 3H, CH3 iPr), 1.42 – 1.50 (m, 2H, CH2), 1.35 (s, 9H, CH3 tBu), 1.30 – 1.40 (m, 2H, CH2), 1.28 (s, 
3H, CH3 iPr), 1.16 – 1.28 (m, 4H, CH2); 13C NMR (CDCl3, 100 MHz): δ 171.1 (C=O), 169.5 (C-4), 156.0, 155.9 
(C=O), 152.5 (C-2), 143.8, 143.5 (Cq, C-6), 141.3 (Cq), 135.7, 127.8, 127.2, 125.1, 120.0 (CHarom), 116.2 (Cq 
iPr), 106.8 (C-5), 93.3 (C-1’), 83.9 (C-2’), 82.3 (C-4’), 80.9 (Cq tBu), 79.0 (C-3’), 67.4 (CH2 Fmoc), 64.5 (C-5’), 
54.0, 52.0 (CH Aza, CH2 Aza), 47.0 (CH Fmoc), 41.9, 40.3, 30.0, 28.8 (CH2), 28.4 (CH3 tBu), 27.1 (CH3 iPr), 
26.5, 26.3 (CH2), 25.2 (CH3 iPr); LC: Rt = 10.19 min; ESI-MS: m/z = 817.33 (M+H+).  
 
 
5’-N-(3-azido-L-alanine)-5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-5’-amino-5’-
deoxy-2’,3’-O-isopropylidene uridine (15). Compound 14 (35 mg, 43 µmol) was 
dissolved in DCM (3 mL) and treated with immobilized piperazine (430 mg, 430-860 
µmol3) for 24 h, after which time the solution was filtered through a syringe filter and 
concentrated at RT. The resulting amine was directly used in the next step without further 
purification. TLC: Rf = 0.29 (DCM/MeOH, 9/1, v/v + 1% Et3N); LC: Rt = 7.32 min; ESI-
MS: m/z = 595.27 (M+H+). 
 
 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 The extent of labeling of commercially available immobilized piperazine is reported to range between 1-2 mmol/g. 
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5’-N-(N-myristoyl-3-azido-L-alanine)-5’-N-(tert-butyl N-[6-aminohexyl] 
carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine (16). Myristic 
acid (20 mg, 86 µmol) was dissolved in DMF (250 µL) and stirred with EDC·HCl 
(16.4 mg, 86 µmol) and HOBt (13 mg, 86 µmol) at RT for 15 min. This solution 
was added to the crude amine 15 (~43 µmol) in DMF (350 µL) and the resulting 
solution was stirred until complete consumption of the starting material was 
observed using LC-MS (2 h). The mixture was diluted with DCM, washed with 
H2O (4x), dried over Na2SO4 and concentrated in vacuo. Purification using flash 
column chromatography (silica gel, 10% MeOH in DCM) afforded the title 
compound as a colorless oil (Yield: 16.7 mg, 21 µmol, 48% over two steps). TLC: Rf = 0.50 (DCM/MeOH, 9/1, 
v/v); 1H NMR (CDCl3, 400 MHz): δ 7.32 (d, 1H, J = 7.7 Hz, H-6), 6.86 (bs, 1H, NH), 5.84 (d, 1H, J = 6.7 Hz, 
H-5), 5.45 (bs, 1H, NH), 5.31 (s, 1H, H-1’), 4.68 – 4.75 (m, 2H, H-2’, H-3’), 4.65 (dt, 1H, J = 4.3, 7.1 Hz, CH 
Aza), 4.56 (bs, 1H, NH), 4.43 – 4.51 (m, 2H, H-4’, H-5’), 4.35 – 4.42 (m, 1H, H-5’), 3.68 (d, 2H, J = 4.3 Hz, 
CH2 Aza), 3.30 – 3.43 (m, 2H, CH2), 2.97 – 3.09 (m, 2H, CH2), 2.10 – 2.25 (m, 2H, CH2), 1.57 (s, 3H, CH3 iPr), 
1.48 – 1.57 (m, 4H, CH2), 1.37 (s, 9H, CH3 tBu), 1.33 (s, 3H, CH3 iPr), 1.27 – 1.43 (m, 6H, CH2), 1.12 – 1.25 
(m, 20H, CH2), 0.81 (t, 3H, J = 6.6 Hz, CH3); 13C NMR (CDCl3, 100 MHz): δ 173.6, 171.2 (C=O), 169.7 (C-4), 
156.1 (C-2), 136.1 (C-6), 116.2 (Cq iPr), 106.5 (C-5), 93.6 (C-1’), 83.9 (C-2’ or C-3’), 82.5 (C-4’), 81.0 (C-2’ or 
C-3’), 79.1 (Cq tBu), 64.4 (C-5’), 52.3, 51.9 (CH Aza, CH2 Aza), 42.0 (CH2), 40.3 (CH2), 36.2, 31.9, 30.0, 29.6, 
29.5, 29.4, 29.3, 28.4, 27.1, 26.5, 26.3, 25.5, 25.2 (CH3, CH3 tBu, CH3 iPr), 22.7 (CH2), 14.1 (CH3); LC: Rt = 
11.50 min; ESI-MS: m/z = 805.40 (M+H+).  
 
 
5’-N-(N-myristoyl-3-azido-L-alanine)-5’-N-(6-aminohexyl)-5’-amino-5’-deoxy 
uridine (17). Compound 16 (4.5 mg, 5.6 µmol) was deprotected according to 
general procedure D to give the title compound as a white solid (Yield: 4.2 mg, 5.35 
µmol, 96%). 1H NMR (DMSO-d6, 600 MHz): δ 8.54 (d, 1H, J = 7.8 Hz, NH), 7.73 
(d, 1H, J = 7.8 Hz, H-6), 5.94 (d, 1H, J = 7.6 Hz, H-5), 5.65 (d, 1H, J = 5.8 Hz, H-
1’), 4.52 (dt, 1H, J = 7.1, 7.1 Hz, CH Aza), 4.30 (d, 2H, J = 3.7 Hz, H-5’), 4.16 – 
4.20 (m, 1H, H-4’), 4.14 (t, 1H, J = 5.5 Hz, H-2’), 4.00 (dd, 1H, J = 4.0, 4.8 Hz, H-
3’), 3.55 – 3.70 (m, 2H, CH2 Aza), 3.30 – 3.36 (m, 2H, CH2), 2.75 – 2.83 (m, 2H, 
CH2), 2.12 – 2.17 (m, 2H, CH2), 1.51 – 1.59 (m, 4H, CH2), 1.44 – 1.51 (m, 2H, CH2), 1.28 – 1.37 (m, 4H, CH2), 
1.18 – 1.27 (m, 20H, CH2), 0.86 (t, 3H, J = 6.7 Hz, CH3); 13C NMR (DMSO-d6, 150 MHz): δ 173.3, 170.1 
(C=O), 169.1 (C-4), 153.3 (C-2), 140.3 (C-6), 105.0 (C-5), 90.0 (C-1’), 83.0 (C-4’), 74.2 (C-2’), 70.0 (C-3’), 
65.0 (C-5’), 52.3 (CH Aza), 51.8 (CH2 Aza), 41.5, 39.3, 35.4, 31.8, 29.5, 29.4, 29.3, 29.2, 29.0, 28.3, 27.3, 26.0, 
25.7, 25.5, 22.6 (CH2), 14.4 (CH3); LC: Rt = 9.84 min; ESI-MS: m/z = 665.40 (M+H+).  
 
 
5’-N-(N-myristoyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-
alanine)-5’-N-(tert-butyl N-[6-aminohexyl]carbamate)-5’-amino-5’-deoxy-
2’,3’-O-isopropylidene uridine (36). Compound 16 (9.6 mg, 11.9 µmol) was 
converted to the title compound using general procedure C (Yield: 9.1 mg, 9.2 
µmol, 77%). TLC: Rf = 0.46 (DCM/MeOH, 9/1, v/v); LC: Rt = 11.90 min; ESI-
MS: m/z = 987.60 (M+H+). Due to rotamerization, the 1H and 13C spectra were 
difficult to interpret. Based on the purity by LC-MS, compound 36 was used in 
the next step, and fully characterized thereafter. 
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5’-N-(N-myristoyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-
alanine)-5’-N-(6-aminohexyl)-5’-amino-5’-deoxy uridine (18). Compound 36 
(~9.2 µmol) was fully deprotected according to general procedure D to give the 
title compound as a slightly colored solid (Yield: 6.9 mg, 7.8 µmol, 85%). 1H 
NMR (DMSO-d6, 600 MHz): δ 8.54 (s, 1H, CHtriazole), 8.50 (d, 1H, J = 7.8 Hz, 
NH), 8.29 (s, 1H, CHarom), 7.85 – 7.92 (m, 3H, CHarom), 7.73 – 7.82 (m, 2H, NH), 
7.52 (d, 1H, J = 7.8 Hz, H-6), 7.34 (d, 1H, J = 2.5 Hz, CHarom), 7.15 – 7.20 (m, 2H, 
CHarom, NH), 5.70 (d, 1H, J = 7.8 Hz, H-5), 5.52 – 5.62 (m, 3H, H-1’, 2’-OH, 3’-
OH), 4.88 – 4.93 (m, 1H, CH Aza), 4.86 (dd, 1H, J = 4.7, 14.0 Hz, CHH Aza), 
4.75 (dd, 1H, J = 9.1, 13.9 Hz, CHH Aza), 4.29 – 4.36 (m, 2H, H-5’), 4.13 – 4.16 
(m, 1H, H-4’), 4.08 – 4.12 (m, 1H, H-2’), 3.99 – 4.03 (m, 1H, H-3’), 3.89 (s, 3H, CH3 OMe), 3.21 – 3.27 (m, 
2H, CH2), 2.75 – 2.83 (m, 2H, CH2), 2.05 (t, 2H, J = 7.3 Hz, CH2), 1.49 – 1.60 (m, 4H, CH2), 1.28 – 1.40 (m, 
4H, CH2), 1.00 – 1.25 (m, 22H, CH2), 0.86 (t, 3H, J = 7.1 Hz, CH3); 13C NMR (DMSO-d6, 150 MHz): δ 173.2, 
170.0 (C=O), 169.7 (C-4), 157.9 (Cq), 153.6 (C-2), 146.9 (Cq), 138.1 (C-6), 134.4 (Cq), 130.0 (CHarom), 129.0 
(Cq), 127.8 (CHarom), 126.3 (Cq), 124.5, 123.8 (CHarom), 122.5 (CHtriazole), 119.6 (CHarom), 106.8 (C-5), 106.4 
(CHarom), 89.3 (C-1’), 82.5 (C-4’), 73.8 (C-2’), 69.9 (C-3’), 65.3 (C-5’), 55.7 (CH3 OMe), 52.6 (CH Aza), 49.9 
(CH2 Aza), 40.5, 39.3, 31.8, 29.6, 29.5, 29.3, 29.2, 28.9, 28.4, 27.1, 25.9, 25.6, 25.4, 22.6 (CH2), 14.4 (CH3); 
LC: Rt = 10.35 min; ESI-MS: m/z = 847.53 (M+H+). 
 
 
5’-N-(O-tert-butyl-L-aspartate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine 
(20). Starting from 5’-amino-5-deoxy-2’,3’-O-isopropylidene uridine 19,4 compound 20 
was obtained using general procedure A (Yield: 82 mg, 180 µmol, 62%). TLC: Rf = 
0.24 (DCM/MeOH, 9/1, v/v + 1% Et3N); 1H NMR (CDCl3, 400 MHz): δ 7.65 (t, 1H, J 
= 5.6 Hz, NH), 7.22 (m, 1H, H-6), 5.67 (d, 1H, J = 8.0 Hz, H-5), 5.46 (d, 1H, J = 2.2 
Hz, H-1’), 4.98 (dd, 1H, J = 2.2, 6.6 Hz, H-2’), 4.71 (dd, 1H, J = 4.7, 6.4 Hz, H-3’), 
4.29 (bs, 2H, NH2), 4.11 (dd, 1H, J = 4.7, 9.5 Hz, H-4’), 3.68 (dd, 1H, J = 4.4, 7.6 Hz, 
CH Asp), 3.61 (dt, 1H, J = 6, 14.2 Hz, H-5’), 3.48 (dt, 1H, J = 4.8, 14.2 Hz, H-5’), 2.78 (dd, 1H, J = 4.3, 16.6 
Hz, CHH Asp), 2.51 (dd, 1H, J = 7.9, 16.6 Hz, CHH Asp), 1.47 (s, 3H, CH3 iPr), 1.37 (s, 9H, CH3 tBu), 1.26 (s, 
3H, CH3 iPr); ); 13C NMR (CDCl3, 100 MHz): δ 173.7, 171.2 (C=O), 163.6 (C-4), 150.3 (C-2), 143.1 (C-6), 
114.7 (Cq iPr), 102.8 (C-5), 95.1 (C-1’), 85.5 (C-4’), 83.9 (C-2’), 81.3, 81.1 (C-3’, Cq tBu), 52.1 (CH Asp), 40.6, 
40.1 (C-5’, CH2 Asp), 28.1 (CH3 tBu), 27.2, 25.3 (CH3 iPr); LC: Rt = 5.77 min; ESI-MS: m/z = 454.93 (M+H+).  
 
 
5’-N-(N-acetyl-L-aspartate)-5’-amino-5’-deoxy uridine (21). Amine 20 (10 mg, 22 
µmol) was dissolved in MeOH (300 µL) and treated with Ac2O (10 µL, 110 µmol) and 
Et3N (15 µL, 110 µmol) for 2 h, after which time the mixture was diluted with toluene 
and concentrated in vacuo. Flash column chromatography (silica gel, 5% MeOH in 
DCM) gave the acetylated intermediate (LC: Rt = 5.91 min; ESI-MS: m/z = 496.93 
(M+H+), which was subsequently treated with TFA/H2O (500 µL, 1/1, v/v) overnight. 
LC-MS confirmed full consumption of the acetylated intermediate, and the reaction mixture was lyophilized to 
give the title compound as a colorless oil (Yield: 7.8 mg, 19 µmol, 86%). 1H NMR (D2O, 600 MHz): δ 7.54 (d, 
1H, J = 8.1 Hz, H-6), 5.77 (d, 1H, J = 8.1 Hz, H-5), 5.68 (d, 1H, J = 4.6 Hz, H-1’), 4.59 (dd, 1H, J = 5.7, 7.4 Hz, 
CH Asp), 4.23 (t, 1H, J = 4.7 Hz, H-2’), 3.98 – 4.02 (m, 2H, H-3’, H-4’), 3.45 – 3.51 (m, 2H, H-5’), 2.80 (dd, 
1H, J = 5.7, 17.1 Hz, CHH Asp), 2.73 (dd, 1H, J = 7.4, 17.0 Hz, CHH Asp), 1.92 (s, 3H, CH3 NHAc); 13C NMR 
(D2O, 150 MHz): δ 174.1, 174.0, 172.9 (C=O), 166.1 (C-4), 151.5 (C-2), 142.2 (C-6), 102.2 (C-5), 90.2 (C-1’), 
81.9 (C-4’), 73.0 (C-2’), 70.3 (C-3’), 50.2 (CH Asp), 40.6 (C-5’), 35.5 (CH2 Asp), 21.8 (CH3 NHAc); LC: Rt = 
1.68 min; ESI-MS: m/z = 400.93 (M+H+). 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 A. Babič, Gobec, S.; C. Gravier-Pelletier, Y. Le Merrer, S. Pečar, Tetrahedron 2008, 64, 9093-9100. 
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5’-N-(N-[9-fluorenylmethoxycarbonyl]-3-azido-L-alaninyl-O-tert-butyl-L-
aspartate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine  (22). Fmoc-L-
Aza-OH (70 mg, 198 µmol) was dissolved in DMF (400 µL) and treated with 
EDC·HCl (41 mg, 216 µmol) and HOBt (33 mg, 216 µmol) for 10 min at RT. 
This mixture was added to compound 20 (82 mg, 180 mmol) and the resulting 
solution was stirred until complete consumption of compound 20 was observed 
using LC-MS (~1 h). The mixture was diluted with DCM, washed with H2O (4x), dried over Na2SO4 and 
concentrated in vacuo. Flash column chromatography (silica gel, 5% MeOH in DCM) afforded the title 
compound as a colorless oil (Yield: 101 mg, 129 µmol, 71%). TLC: Rf = 0.47 (DCM/MeOH, 9/1, v/v); 1H NMR 
(CDCl3, 400 MHz): δ 9.83 (bs, 1H, NH), 7.68 (d, 2H, J = 7.5 Hz, CHarom), 7.48 – 7.59 (m, 2H, CHarom), 7.32 (t, 
2H, J = 7.5 Hz, CHarom), 7.23 (t, 2H, J = 7.5 Hz, CHarom), 7.10 (d, 1H, J = 8.0 Hz, H-6), 5.76 (bs, 1H, NH), 5.67 
(dd, 1H, J = 2.0, 8.0 Hz, H-5), 5.24 (s, 1H, H-1’), 5.00 (d, 1H, J = 6.1 Hz, H-2’), 4.68 – 4.77 (m, 2H, H-3’, CH 
Asp), 4.50 – 4.58 (m, 1H, CH Aza), 4.35 – 4.50 (m, 2H, CH2 Fmoc), 4.16 (t, 1H, J = 6.7 Hz, CH Fmoc), 4.10 (s, 
1H, H-4’), 3.78 (dd, 1H, J = 3.6, 11.8 Hz, CHH Aza), 3.62 – 3.71 (m, 1H, H-5’), 3.52 (dd, 1H, J = 5.2, 11.9 Hz, 
CHH Aza), 3.37 – 3.45 (m, 1H, H-5’), 2.82 – 2.90 (m, 1H, CHH Asp), 2.57 (dd, 1H, J = 5.3, 16.8 Hz, CHH 
Asp), 1.45 (s, 3H, CH3 iPr), 1.30 (s, 9H, CH3 tBu), 1.24 (s, 3H, CH3 iPr); 13C NMR (CDCl3, 100 MHz): δ 170.9, 
170.5 (C=O), 169.3 (C-4), 162.7, 156.5 (C=O), 150.7 (C-2), 143.6, 143.5 (Cq, C-6), 141.3 (Cq), 127.8, 127.2, 
125.0, 120.0 (CHarom), 114.8 (Cq iPr), 102.9 (C-5), 96.2 (C-1’), 84.7 (C-4’), 83.5 (C-2’), 81.8 (Cq tBu), 80.3 (C-
3’), 67.7 (CH2 Fmoc), 54.3, 52.0, 50.0 (CH Aza, CH Asp, CH2 Aza), 47.1 (CH Fmoc), 40.8 (C-5’), 36.9 (CH2 
Asp), 28.0 (CH3 tBu), 27.3, 25.3 (CH3 iPr); LC: Rt = 9.51 min; ESI-MS: m/z = 789.07 (M+H+). 
 
 
5’-N-(3-azido-L-alaninyl-O-tert-butyl-L-aspartate)-5’-amino-5’-deoxy-2’,3’-O-
isopropylidene uridine (23). Compound 22 (35 mg, 44 µmol) was dissolved in 
DCM (2.5 mL) and treated with immobilized piperazine (440 mg, 440-880 µmol3) 
for 24 h, after which time the solution was filtered through a syringe filter and 
concentrated at RT. The resulting amine was directly used in the next step without 
further purification. LC: Rt = 5.95 min; ESI-MS: m/z = 567.07 (M+H+). 
 
 
5’-N-(N-acetyl-3-azido-L-alaninyl-O-tert-butyl-L-aspartate)-5’-amino-5’-
deoxy-2’,3’-O-isopropylidene uridine (24). The crude amine 23 (9 mg, 16 
µmol) was dissolved in MeOH (400 µL) and treated with Ac2O (7.7 µL, 82 
µmol) and Et3N (11.4 µL, 82 µmol) for 2 h, after which time the mixture was 
diluted with toluene and concentrated in vacuo. Flash column chromatography 
(silica gel, 5% MeOH in DCM) gave the title compound as a white solid (Yield: 
9 mg, 14.6 µmol, 89%). TLC: Rf = 0.44 (DCM/MeOH, 9/1, v/v); 1H NMR 
(CDCl3, 400 MHz): δ 9.92 (s, 1H, NH), 7.47 (d, 1H, J = 8.9 Hz, NH), 7.23 (dd, 
1H, J = 4.3, 5.6 Hz, NH), 7.14 (d, 1H, J = 8.1 Hz, H-6), 6.49 (d, 1H, J = 8.4 Hz, NH), 5.70 (dd, 1H, J = 2.1, 8.0 
Hz, H-5), 5.27 (d, 1H, J = 2.4 Hz, H-1’), 5.05 (dd, 1H, J = 2.3, 6.6 Hz, H-2’), 4.82 (ddd, 1H, J = 4.6, 5.7, 8.4 
Hz, CH Aza), 4.72 – 4.77 (m, 2H, H-3’, CH Asp), 4.13 (dt, 1H, J = 3.3, 4.9 Hz, H-4’), 3.77 (dd, 1H, J = 4.6, 
12.4 Hz, CHH Aza), 3.67 (ddd, 1H, J = 3.3, 6.3, 14.6 Hz, H-5’), 3.53 (dd, 1H, J = 5.7, 12.4 Hz, CHH Aza), 3.47 
(dt, 1H, J = 3.7, 14.7 Hz, H-5’), 2.85 (dd, 1H, J = 5.1, 16.7 Hz, CHH Asp), 2.58 (dd, 1H, J = 5.3, 16.7 Hz, CHH 
Asp), 2.03 (s, 3H, CH3 NHAc), 1.48 (s, 3H, CH3 iPr), 1.34 (s, 9H, CH3 tBu), 1.27 (s, 3H, CH3 iPr); 13C NMR 
(CDCl3, 100 MHz): δ 171.0, 170.5 (C=O), 169.2 (C-4), 163.0 (C=O), 150.9 (C-2), 143.5 (C-6), 114.9 (Cq iPr), 
103.0 (C-5), 96.7 (C-1’), 84.8 (C-4’), 83.6 (C-2’), 81.9 (Cq tBu), 80.1 (C-3’), 52.3, 51.7, 50.0 (CH Aza, CH Asp, 
CH2 Aza), 40.8 (C-5’), 37.0 (CH2 Asp), 28.0 (CH3 tBu), 27.3, 25.3 (CH3 iPr), 23.2 (CH3 NHAc); LC: Rt = 6.55 
min; ESI-MS: m/z = 608.93 (M+H+). 
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5’-N-(N-acetyl-3-azido-L-alaninyl-L-aspartate)-5’-amino-5’-deoxy uridine 
(25). Compound 24 was fully deprotected using general procedure D to afford 
the title compound as a white solid (Yield: 1.75 mg, 3.42 µmol, 83%). 1H NMR 
(D2O, 600 MHz): δ 7.57 (d, 1H, J = 8.1 Hz, H-6), 5.81 (d, 1H, J = 8.1 Hz, H-5), 
5.69 (d, 1H, J = 4.4 H-1’), 4.60 – 4.75 (m, 1H, CH Asp), 4.43 (t, 1H, J = 5.5 Hz, 
CH Aza), 4.26 (t, 1H, J = 4.7 Hz, H-2’), 4.97 – 4.05 (m, 2H, H-3’, H-4’), 3.66 
(dd, 1H, J = 6.0, 12.9 Hz, CHH Aza), 3.59 (dd, 1H, J = 5.2, 12.9 Hz, CHH Aza), 3.48 – 3.53 (m, 2H, H-5’), 2.87 
(dd, 1H, J = 5.9, 16.9 Hz, CHH Asp), 2.76 (dd, 1H, J = 7.4, 16.9 Hz, CHH Asp), 1.95 (s, 3H, CH3 NHAc); 13C 
NMR (D2O, 150 MHz): δ 174.6, 174.0, 172.2, 171.2 (C=O), 166.2 (C-4), 151.5 (C-2), 142.4 (C-6), 102.3 (C-5), 
90.5 (C-1’), 81.8 (C-4’), 73.0 (C-2’), 70.2 (C-3’), 53.2 (CH Aza), 50.9 (CH2 Aza), 50.1 (CH Asp), 40.6 (C-5’), 
35.2 (CH2 Asp), 21.6 (CH3 NHAc); LC: Rt = 1.61 min; ESI-MS: m/z = 513.07 (M+H+). 
 
 
5’-N-(N-acetyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-alaninyl-
O-tert-butyl-L-aspartate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine 
(37). Compound 24 was converted to the title compound using general procedure 
C. TLC: Rf = 0.41 (DCM/MeOH, 9/1, v/v); LC: Rt = 8.26 min; ESI-MS: m/z = 
791.20 (M+H+). In spite of extensive purification, the NMR spectra were 
difficult to interpret. Purity and identify of compound 37 were assessed through 
LC-MS, and the compound was extensively characterized after the subsequent 
reaction step. 
 
 
 
 
 
5’-N-(N-acetyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-alaninyl-L-
aspartate)-5’-amino-5’-deoxy uridine (26). The title compound was obtained 
from compound 37 using general procedure D (Yield: 2.1 mg, 3.0 mmol, 61% 
over two steps). 1H NMR (DMSO-d6, 600 MHz): δ 11.36 (s, 1H, NH), 8.59 (d, 
1H, J = 7.7 Hz, NH), 8.54 (s, 1H, CHtriazole), 8.32 (s, 1H, CHarom), 8.29 (d, 1H, J = 
7.9 Hz, NH), 8.11 (t, 1H, J = 5.8 Hz, NH), 7.88 – 7.94 (m, 3H, CHarom), 7.68 (d, 
1H, J = 8.0 Hz, H-6), 7.35 (d, 1H, J = 2.0 Hz, CHarom), 7.19 (dd, 1H, J = 2.4, 8.9 
Hz, CHarom), 5.76 (d, 1H, J = 6.1 Hz, H-1’), 5.62 (dd, 1H, J = 1.9, 8.0 Hz, H-5), 
5.42 (d, 1H, J = 5.8 Hz, 2’-OH), 5.19 (d, 1H, J = 4.8 Hz, 3’-OH), 4.81 – 4.86 (m, 
1H, CH Aza), 4.79 (dd, 1H, J = 4.6, 14.0 Hz, CHH Aza), 4.64 (dd, 1H, J = 7.4, 
14.2 Hz, CHH Aza), 4.57 – 4.61 (m, 1H, CH Asp), 4.05 – 4.09 (m, 1H, H-2’), 
3.86 – 3.93 (m, 5H, H-3’, H-4’, CH3 OMe), 3.30 – 3.45 (m, 2H, H-5’), 2.73 (dd, 1H, J = 5.2, 16.7 Hz, CHH 
Asp), 2.57 (dd, 1H, J = 8.0, 16.7 Hz, CHH Asp), 1.85 (s, 3H, CH3 NHAc); 13C NMR (DMSO-d6, 150 MHz): δ 
172.2, 171.1, 170.3 (C=O), 169.0 (C-4), 163.5, 157.9 (Cq), 151.2 (C-2), 146.8 (Cq), 141.7 (C-6), 134.3 (Cq), 
132.0, 131.9, 130.0, 129.3, 129.2, 129.0, 127.9 (CHarom), 126.4 (Cq), 124.6, 123.9 (CHarom), 122.6 (CHtriazole), 
119.6, 106.5 (CHarom), 102.4 (C-5), 88.3 (C-1’), 83.0 (C-4’), 72.9 (C-2’), 71.2 (C-3’), 55.7 (CH3 OMe), 53.2 
(CH Aza), 51.1 (CH2 Aza), 50.3 (CH Asp), 41.6 (C-5’), 36.5 (CH2 Asp), 22.9 (CH3 NHAc); LC: Rt = 6.43 min; 
ESI-MS: m/z = 695.20 (M+H+). 
 
 
5’-N-(N-myristoyl-3-azido-L-alaninyl-O-tert-butyl-L-aspartate)-5’-
amino-5’-deoxy-2’,3’-O-isopropylidene uridine (27). Myristic acid (19 
mg, 82 µmol) was dissolved in DMF (200 µL) and stirred with EDC·HCl 
(16 mg, 82 µmol) and HOBt (13 mg, 82 µmol) at RT for 15 min. This 
solution was added to the crude amine 23 (~41 µmol) in DMF (200 µL) and 
the resulting solution was stirred until complete consumption of the starting 
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material was observed using LC-MS (2 h). The mixture was diluted with DCM, washed with H2O (4x), dried 
over Na2SO4 and concentrated in vacuo. Purification using flash column chromatography (silica gel, 5% MeOH 
in DCM) afforded the title compound as a colorless oil (Yield: 20 mg, 26 µmol, 63% over two steps). TLC: Rf = 
0.41 (DCM/MeOH, 9/1, v/v); 1H NMR (CDCl3, 400 MHz): δ 10.04 (s, 1H, NH), 7.54 (d, 1H, J = 8.9 Hz, NH), 
7.24 (dd, 1H, J = 4.0, 6.2 Hz, NH), 7.15 (d, 1H, J = 8.1 Hz, H-6), 6.55 (d, 1H, J = 6.9 Hz, NH), 5.69 (d, 1H, J = 
8.0 Hz, H-5), 5.29 (d, 1H, J = 2.3 Hz, H-1’), 5.03 (dd, 1H, J = 2.2, 6.6 Hz, H-2’), 4.82 (dt, 1H, J = 5.2, 8.0 Hz, 
CH Aza), 4.72 – 4.78 (m, 2H, H-3’, CH Asp), 4.10 – 4.15 (m, 1H, H-4’), 3.75 (dd, 1H, J = 4.7, 12.5 Hz, CHH 
Aza), 3.65 (ddd, 1H, J = 3.3, 6.2, 14.7 Hz, H-5’), 3.53 (dd, 1H, J = 5.7, 12.4 Hz, CHH Aza), 3.47 (dt, 1H, J = 
3.6, 14.6 Hz, H-5’), 2.85 (app dd, 1H, J = 5.0, 16.8 Hz, CHH Asp), 2.56 (dd, 1H, J = 5.3 Hz, 16.8 Hz, CHH 
Asp), 2.18 – 2.25 (m, 2H, CH2), 1.52-1.63 (m, 2H, CH2), 1.48 (s, 3H, CH3 iPr), 1.33 (s, 9H, CH3 tBu), 1.27 (s, 
3H, CH3 iPr), 1.15 – 1.26 (m, 20H, CH2), 0.81 (t, 3H, J = 6.8 Hz, CH3); 13C NMR (CDCl3, 100 MHz): δ 170.9, 
170.6 (C=O), 169.4 (C-4), 163.1, 162.6 (C=O), 150.9 (C-2), 143.4 (C-6), 114.8 (Cq iPr), 103.0 (C-5), 96.4 (C-
1’), 84.7 (C-4’), 83.6 (C-2’), 81.8 (Cq tBu), 80.1 (C-3’), 52.2 (CH Aza), 51.7 (CH2 Aza), 50.0 (CH Asp), 40.8 
(C-5’), 36.9 (CH2 Asp), 36.5, 31.9, 29.7, 29.6, 29.5, 29.3, 29.3, 29.1 (CH2), 28.0 (CH3 tBu), 27.3 (CH3 iPr), 
25.5, 25.3 (CH3 iPr, CH2), 22.7 (CH2), 14.1 (CH3); LC: Rt = 11.41 min; ESI-MS: m/z = 777.07 (M+H+). 
 
 
5’-N-(N-myristoyl-3-azido-L-alaninyl-L-aspartate)-5’-amino-5’-deoxy 
uridine (28). Compound 27 was fully deprotected using general procedure 
D to afford the title compound as an off-white solid (Yield: 3.0 mg, 4.4 
µmol, quant.). 1H NMR (DMSO-d6, 600 MHz): δ 8.33 (d, 1H, J = 7.3 Hz, 
NH), 8.26 (d, 1H, J = 8.0 Hz, NH), 7.92 (t, 1H, J = 5.7 Hz, NH), 7.66 (d, 
1H, J = 8.1 Hz, H-6), 5.73 (d, 1H, J = 5.8 Hz, H-1’), 5.65 (d, 1H, J = 8.0 Hz, 
H-5), 5.39 (d, 1H, J = 5.6 Hz, 2’-OH), 4.50 – 4.57 (m, 2H, CH Asp, CH Aza), 3.98 – 4.03 (m, 1H, H-2’), 4.83 – 
4.87 (m, 1H, H-3’), 3.77 – 3.82 (m, 1H, H-4’), 3.53 (dd, 1H, J = 4.5, 12.6 Hz, CHH Aza), 3.40 – 3.46 (m, 1H, 
CHH Aza), 3.28 – 3.39 (m, 2H, H-5’), 2.66 (dd, 1H, J = 5.6, 16.6 Hz, CHH Asp), 2.53 – 2.56 (m, 1H, CHH 
Asp), 2.12 – 2.17 (m, 2H, CH2), 1.45 – 1.53 (m, 2H, CH2), 1.20 – 1.30 (m, 20H, CH2), 0.86 (t, 3H, J = 6.7 Hz, 
CH3); 13C NMR (DMSO-d6, 150 MHz): δ 173.3, 172.2, 171.0 (C=O), 169.6 (C-4), 163.5 (C=O), 151.2 (C-2), 
141.7 (C-6), 102.4 (C-5), 88.4 (C-1’), 83.0 (C-4’), 72.9 (C-2’), 71.0 (C-3’), 52.7, 52.0 (CH Aza, CH2 Aza), 50.1 
(CH Asp), 41.5 (C-5’), 36.6 (CH2 Asp), 35.6, 31.8, 29.5, 29.4, 29.3, 29.2, 29.1, 25.5, 22.6 (CH2), 14.4 (CH3); 
LC: Rt = 9.84 min; ESI-MS: m/z = 681.20 (M+H+). 
 
 
5’-N-(N-myristoyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-
alaninyl-O-tert-butyl-L-aspartate)-5’-amino-5’-deoxy-2’,3’-O-
isopropylidene uridine (38). The title compound was obtained from 
compound 27 according to general procedure C (8.4 mg, 8.8 µmol, 93%). 
TLC: Rf = 0.60 (DCM/MeOH, 9/1, v/v); 1H NMR (CDCl3/MeOH-d4, 400 
MHz): δ 8.17 (s, 1H, CHarom), 7.97 (s, 1H, CHtriazole), 7.81 (dd, 1H, J = 1.6, 
8.5 Hz, CHarom), 7.72 – 7.77 (m, 2H, CHarom), 7.25 (d, 1H, J = 8.0 Hz, H-6), 
7.09 – 7.15 (m, 2H, CHarom), 5.64 (d, 1H, J = 8.0 Hz, H-5), 5.40 (d, 1H, J = 
2.5 Hz, H-1’), 4.98 – 5.03 (m, 2H, H-2’, CH Aza), 4.86 (dd, 1H, J = 5.6, 
14.2 Hz, CHH Aza), 4.70 – 4.81 (m, 3H, H-3’, CH Asp, CHH Aza), 4.15 – 
4.20 (m, 1H, H-4’), 3.90 (s, 3H, CH3 OMe), 3.64 (dd, 1H, J = 3.8, 14.4 Hz, 
H-5’), 3.53 (dd, 1H, J = 4.1, 14.4 Hz, H-5’), 2.70 (dd, 1H, J = 6.0, 16.7 Hz, CHH Asp), 2.63 (dd, 1H, J = 5.7, 
16.7 Hz, CHH Asp), 2.21 (t, 2H, J = 7.5 Hz, CH2), 1.51 – 1.60 (m, 2H, CH2), 1.48 (s, 3H, CH3 iPr), 1.34 (s, 9H, 
CH3 tBu), 1.27 (s, 3H, CH3 iPr), 1.12 – 1.24 (m, 20H, CH2), 0.83 (t, 3H, J = 6.7 Hz, CH3); 13C NMR 
(CDCl3/MeOH-d4, 100 MHz): δ 174.8, 170.7 (C=O), 168.7 (C-4), 163.7 (C=O), 158.0 (Cq), 150.8 (C-2), 148.0 
(Cq), 143.2 (C-6), 134.5 (Cq), 129.7 (CHarom), 128.9 (Cq), 127.5 (CHarom), 125.0 (Cq), 124.4, 124.1 (CHarom), 
121.4 (CHtriazole), 119.3 (CHarom), 114.7 (Cq iPr), 105.8 (CHarom), 102.7 (C-5), 95.5 (C-1’), 84.5 (C-4’), 83.5 (C-
2’), 81.8 (Cq tBu), 80.5 (C-3’), 55.3 (OMe), 52.8 (CH Aza), 50.4 (CH2 Aza), 49.8 (CH Asp), 40.5 (C-5’), 36.8 
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(CH2 Asp), 36.2 (CH2), 31.8, 29.6, 29.5, 29.4, 29.3, 29.2 (CH2), 27.8 (CH3 tBu), 27.1 (CH3 iPr), 25.5 (CH2), 
25.2 (CH3 iPr), 22.6, 14.0 (CH2); LC: Rt = 12.01 min; ESI-MS: m/z = 959.40 (M+H+).  
 
 
5’-N-(N-myristoyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-
alaninyl-L-aspartate)-5’-amino-5’-deoxy uridine (29). Compound 38 was 
fully deprotected using general procedure D to afford the title compound as 
a slightly colored solid (Yield: 5.1 mg, 5.9 µmol, 66%).  1H NMR (DMSO-
d6, 600 MHz): δ 11.4 (s, 1H, NH), 8.53 (d, 1H, J = 7.7 Hz, NH), 8.48 (s, 1H, 
CHtriazole), 8.28 (s, 1H, CHarom), 8.21 (d, 1H, J = 8.2 Hz, NH), 8.11 (t, 1H, J = 
5.6 Hz, NH), 7.86 – 7.92 (m, 3H, CHarom), 7.68 (d, 1H, J = 8.0 Hz, H-6), 
7.33 (d, 1H, J = 1.9 Hz, CHarom), 7.18 (dd, 1H, J = 2.3, 8.9 Hz, CHarom), 5.75 
(d, 1H, J = 5.9 Hz, H-1’), 5.64 (dd, 1H, J = 1.3, 7.8 Hz, H-5), 5.41 (d, 1H, J 
= 5.7 Hz, 2’-OH), 5.18 (d, 1H, J = 4.4 Hz, 3’-OH), 4.87 – 4.92 (m, 1H, CH 
Aza), 4.82 (dd, 1H, J = 4.1, 14.0 Hz, CHH Aza), 4.57 – 4.62 (m, 2H, CH 
Asp, CHH Aza), 4.04 – 4.08 (m, 1H, H-2’), 3.85 – 3.92 (m, 5H, H-3’, H-4’, CH3 OMe), 3.40 – 3.45 (m, 2H, H-
5’), 2.71 (dd, 1H, J = 4.5, 16.8 Hz, CHH Asp), 2.57 – 2.61 (m, 1H, CHH Asp), 2.02 – 2.13 (m, 2H, CH2), 1.29 – 
1.38 (m, 2H, CH2), 0.95 – 1.26 (m, 20H, CH2), 0.86 (t, 3H, J = 7.0 Hz, CH3); 13C NMR (DMSO-d6, 150 MHz): 
δ 173.1, 171.1 (C=O), 169.2 (C-4), 163.5 (C=O), 157.9 (Cq), 151.2 (C-2), 146.7 (Cq), 141.7 (C-6), 134.3 (Cq), 
130.0, 129.0, 127.8 (CHarom), 126.4 (Cq) 124.5, 123.8 (CHarom), 122.5 (CHtriazole), 119.5, 106.4 (CHarom), 102.4 
(C-5), 88.4 (C-1’), 83.0 (C-4’), 73.0 (C-2’), 71.2 (C-3’), 55.7 (CH3 OMe), 52.9 (CH Aza), 50.9 (CH2 Aza), 50.3 
(CH Asp), 41.6 (C-5’), 35.7 (CH2 Asp), 31.8, 29.5, 29.4, 29.3, 29.2, 29.0, 25.6, 22.6 (CH2),14.4 (CH3); LC: Rt = 
10.45 min; ESI-MS: m/z = 863.3 (M+H+).  
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Overview of the click library based on azides 11, 12 and 13 (synthesized using general procedure B) 
 
Compound Structure LC-MS data 
11a 
 
Rt = 7.35 min 
m/z = 552.20 (M+H+) 
11f 
 
Rt = 6.15 min 
m/z = 502.13 (M+H+) 
11g 
 
Rt = 6.61 min 
m/z = 582.20 (M+H+) 
11h 
 
Rt = 6.07 min 
m/z = 496.20 (M+H+) 
11i 
 
Rt = 2.00 min 
m/z = 473.07 (M+H+) 
12a 
 
Rt = 8.04 min 
m/z = 580.27 (M+H+) 
12f 
 
Rt = 6.13 min 
m/z = 530.27 (M+H+) 
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12g 
 
Rt = 6.52 min 
m/z = 611.27 (M+H+) 
12h 
 
Rt = 5.89 min 
m/z = 525.27 (M+H+) 
12i 
 
Rt = 2.03 min 
m/z = 501.20 (M+H+) 
13a 
 
Rt = 6.98 min 
m/z = 608.27 (M+H+) 
13b 
 
Rt = 6.93 min 
m/z = 650.33 (M+16+H+) 
13c 
 
Rt = 8.18 min 
m/z = 584.33 (M+H+) 
13d 
 
Rt = 7.77 min 
m/z = 604.33 (M+H+) 
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13e 
 
Rt = 4.95 min 
m/z = 571.33 (M+H+) 
13f 
 
Rt = 6.10 min 
m/z = 558.33 (M+H+) 
13g 
 
Rt = 6.70 min 
m/z = 639.33 (M+H+) 
13h 
 
Rt = 6.16 min 
m/z = 553.27 (M+H+) 
13i 
 
Rt = 1.94 min 
m/z = 529.27 (M+H+) 
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Chemo-enzymatic synthesis of radiolabeled UDP-diNAcBac 
[3H]-UDP-diNAcBac was prepared by previously described chemoenzymatic methods, with a modification at 
the final step to incorporate the tritium radiolabel.5 UDP-GlcNAc was converted to UDP-4-amino-NAcBac 
using PglF and PglE. After purification, 5 mM UDP-4-amino-NAcBac was incubated with [3H]-Acetyl 
coenzyme A (20 Ci/mmol, American Radiolabeled Chemicals), 50 mM HEPES pH 7.5, 50 mM NaCl, and 260 
µM PglD, followed by a chase with 5 mM unlabeled acetyl coenzyme A for 2 hours. The radiolabeled product 
was purified on a Phenomenex Synergi C18 reverse-phase HPLC column, to yield [3H]-UDP-diNAcBac (5.4 
mCi/mmol).  
 
 
Purification of PglC 
PglC was cloned into the pET-SUMO vector (Life Technologies) using the BsaI and XhoI restriction sites and 
the following primers:  
 
PglC Forward Primer 5′-CGCCGGTCTCCAGGTATGTATGAAAAA-3′ 
PglC Reverse Primer 5′-ATCGCTCGAGTTATGCCGTCCCGGTCTT-3′ 
 
The pET-SUMO-PglC plasmid was transformed into BL21-RIL cells (Agilent) for overexpression, using 
kanamycin and chloramphenicol for selection. Overexpression was performed using the Studier method.19 In 
this method, 1 mL of an overnight cell culture was added to expression media containing 30 µg/mL kanamycin 
and 30 µg/mL chloramphenicol in 1 L of autoinduction media (0.1% (w/v) tryptone, 0.05% (w/v) yeast extract, 
2 mM MgSO4, 0.05% (v/v) glycerol, 0.005% (w/v) glucose, 0.02% (w/v) α-lactose, 2.5 mM Na2HPO4, 2.5 mM 
KH2PO4, 5 mM NH4Cl, 0.5 mM Na2SO4). Cells were allowed to grow with shaking for 3 h at 37 °C. After 3 h, 
the temperature was decreased to 16 °C, and the cells were incubated for 16 hours. Cells were harvested by 
centrifuging at 9000 x g, and cells were stored at -80 °C. Cell pellets were thawed in 10% of the original culture 
volume in 50 mM Tris pH 8.0, 150 mM NaCl, 40 µL protease inhibitor cocktail (Calbiochem). The cells were 
lysed by two rounds of sonication for 90 seconds each, at an amplitude of 50% with one-second on/off pulses. 
The cells were incubated on ice for ten minutes between rounds of sonication. Cellular debris was removed by 
centrifugation at 9000 x g for 45 minutes. The resulting supernatant was transferred to a clean centrifuge tube 
and subjected to centrifugation at 142,000 x g for 65 minutes to pellet the CEF. If the CEF was to be used for 
activity assays, it was homogenized into 1% of the original culture volume in 50 mM HEPES pH 7.5, 100 mM 
NaCl and stored at -80 °C. If protein was to be purified from the CEF, it was isolated and homogenized into 
10% of the original culture volume in 50 mM HEPES pH 7.5, 100 mM NaCl, 1% n-dodecyl beta-D-maltoside 
(DDM), using a glass homogenizer. 20 µL protease inhibitor cocktail was added to prevent proteolysis. This 
sample was incubated at 4 °C with gentle rocking for 16 hours, after which it was centrifuged (145,000 x g) to 
remove insoluble material. The resulting supernatant was incubated with 1 mL Ni-NTA resin for 1-2 hours. The 
resin was washed with 30 ml Wash 1 buffer (50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% DDM, 20 mM 
imidazole), followed by a wash with 30 ml Wash 2 buffer (50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% DDM, 
45 mM imidazole). PglC was eluted in 4 x 1 mL fractions of elution buffer (50 mM HEPES pH 7.5, 100 mM 
NaCl, 0.03% DDM, 300 mM imidazole). Gel filtration analysis was performed using a Superdex S200 10/300 
column (GE Healthcare) equilibrated with 50 mM HEPES pH 7.5, 100 mM NaCl, and 0.03% DDM. 
 
  
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 N. B. Olivier, M. M. Chen, J. R. Behr, B. Imperiali, Biochemistry 2006, 45, 13659-13669. 
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Radioactivity-Based Activity Assays with PglC.  
Assays contained 20 µM Und-P, 10% DMSO, 0.1% Triton X-100, 50 mM HEPES pH 7.5, 100 mM NaCl, 5 
mM MgCl2, 20 µM [3H]-UDP-diNAcBac, and 1 nM PglC in a final volume of 60 µL. Inhibitors were added in 
DMSO, in a volume such that the total concentration of DMSO in the reaction was equal to 10% (v/v). PglC was 
pre-incubated in the reaction mixture lacking [3H]-UDP-diNAcBac for five minutes at RT. After initiation of the 
reaction with [3H]-UDP-diNAcBac, aliquots (20 µL) were taken at twenty minute time points and quenched in 1 
mL CHCl3:MeOH. The organic layer was washed three times with 400 µL PSUP (Pure Solvent Upper Phase, 
composed of 15 mL CHCl3, 240 mL MeOH, 1.83 g KCl in 235 mL H2O). The resulting aqueous layers were 
combined with 5 mL EcoLite (MP Biomedicals) liquid scintillation cocktail. Organic layers were combined with 
5 mL OptiFluor (PerkinElmer). Both layers were analyzed using scintillation counting. Conversion was 
calculating by dividing the radioactive counts in the organic layer over the total number of counts. The data was 
plotted as percentage remaining activity compared to the positive control (no inhibitor), and the IC50 values were 
obtained by plotting residual activity versus concentration (GraphPad Prism). 
Luminescence assay using UMP/CMP-Glo.  
The quenching solution was prepared as described by Promega. Assays contained 20 µM Und-P, 10% DMSO, 
0.1% Triton X-100, 50 mM HEPES pH 7.5, 100 mM NaCl, 5 mM MgCl2, 20 µM UDP-diNAcBac, and 1 nM 
PglC in a final volume of 25 µL. Inhibitors were added in DMSO, in a volume such that the total concentration 
of DMSO in the reaction was equal to 10% (v/v). PglC was pre-incubated in the reaction mixture lacking UDP-
diNAcBac for five minutes at RT. After initiation of the reaction with UDP-diNAcBac, the reaction was halted 
after 20 min by the addition of 25 µL quenching buffer. The mixture was transferred to a 96-well plate (white, 
half area, Corning) and placed in the plate reader. The plate was shaken at low speed for 16 min, and incubated 
at RT for 44, after which time the luminescence was read. Background inhibition of the UMP/CMP-Glo assay 
was established for each inhibitor,6 and the luminescent reads were adjusted accordingly. Conversion was 
calculating by dividing the luminescence units (RLU) in the sample with inhibitor over the RLU obtained for the 
positive control (no inhibitor). The data was plotted as percentage remaining activity compared to the positive 
control (no inhibitor), and the IC50 values were obtained by plotting residual activity versus concentration 
(GraphPad Prism). 
 
 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6  Some inhibitors, especially the first-and second-generation scaffolds, inhibited the UMP/CMP-Glo assay itself. 
Fortunately, the more elaborate compounds and end products were not inhibiting the assay.  
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Michaelis Menten plots for UDP-diNAcBac and Und-P 
Kinetic parameters were determined for each of the substrates of the PglC reaction. The radioactivity-based 
assay was used to determine the KM of UDP-diNAcBac, at 20 µM Und-P, while the UMP/CMP-Glo assay was 
used to determine the KM of Und-P, at 20 µM UDP-diNAcBac. An important caveat for the determination of 
kinetic parameters for Und-P is that it is difficult to predict how this substrate is distributed among detergent 
micelles that contain PglC, and it is not apparent what the effective concentration of Und-P is in the 
microenvironment of the micelles. Thus, the reported parameters for Und-P are apparent values. The data was fit 
to a Michaelis Menten plot using non-linear regression. 
 
 
 
 
 
 
 
 
 
 
  
 KM app Vmax app kcat 
UDP-diNAcBac 7.2 ± 1.1 µM 1.84 ± 0.09 µM/min 303 ± 90 min-1 
Und-P 15.6 ± 5.1 µM 0.3 ± 0.04 µM/min 460 ± 10 min-1 
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5’-N-(tert-butyl N-[2-aminoethyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine (2).  
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5’-N-(tert-butyl N-[4-aminobutyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine (3).  
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5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine (4).	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5’-N-(2-aminoethyl)-5’-amino-5’-deoxy-uridine (5). 
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5’-N-(4-aminobutyl)-5’-amino-5’-deoxy-uridine (6). 
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5’-N-(6-aminohexyl)-5’-amino-5’-deoxy-uridine (7). 
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5’-N-(N-acetyl-D/L-alanine)-5’-N-(tert-butyl N-[2-aminoethyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-
isopropylidene uridine (30). 
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5’-N-(N-acetyl-D/L-alanine)-5’-N-(2-aminoethyl)-5’-amino-5’-deoxy-uridine (8). 
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5’-N-(N-acetyl-D/L-alanine)-5’-N-(tert-butyl N-[4-aminobutyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-
isopropylidene uridine (31). 
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5’-N-(N-acetyl-D/L-alanine)-5’-N-(4-aminobutyl)-5’-amino-5’-deoxy-uridine (9). 
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5’-N-(N-acetyl-D/L-alanine)-5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-
isopropylidene uridine (32). 
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5’-N-(N-acetyl-D/L-alanine)-5’-N-(6-aminohexyl)-5’-amino-5’-deoxy- uridine (10). 	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5’-N-azidoacetyl-5’-N-(tert-butyl N-[2-aminoethyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene 
uridine (33). 
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deoxy-uridine (11). 
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5’-N-azidoacetyl-5’-N-(tert-butyl N-[4-aminobutyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene 
uridine (34). 
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5’-N-azidoacetyl-5’-N-(4-aminobutyl)-5’-amino-5’-deoxy-uridine (12). 
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5’-N-azidoacetyl-5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene 
uridine (35). 
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5’-N-azidoacetyl-5’-N-(6-aminohexyl)-5’-amino-5’-deoxy-uridine (13). 
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5’-N-(N-[9-fluorenylmethoxycarbonyl]-3-azido-L-alanine)-5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-
5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine (14). 
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5’-N-(3-azido-L-alanine)-5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-5’-amino-5’-deoxy-2’,3’-O-
isopropylidene uridine (15). 
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5’-N-(N-myristoyl-3-azido-L-alanine)-5’-N-(tert-butyl N-[6-aminohexyl] carbamate)-5’-amino-5’-deoxy-
2’,3’-O-isopropylidene uridine (16). 
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5’-N-(N-myristoyl-3-azido-L-alanine)-5’-N-(6-aminohexyl)-5’-amino-5’-deoxy uridine (17). 
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5’-N-(N-myristoyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-alanine)-5’-N-(6-aminohexyl)-5’-
amino-5’-deoxy uridine (18). 
5’-N-(O-
tert-
butyl-L-
aspartate
)-5’-
amino-
5’-deoxy-
2’,3’-O-
isopropyl
idene 
uridine 
(20). 
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5’-N-(N-acetyl-L-aspartate)-5’-amino-5’-deoxy uridine (21). 
Acetylated intermediate 
Final compound 21 
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5’-N-(N-[9-fluorenylmethoxycarbonyl]-3-azido-L-alaninyl-O-tert-butyl-L-aspartate)-5’-amino-5’-deoxy-
2’,3’-O-isopropylidene uridine  (22). 
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5’-N-(3-azido-L-alaninyl-O-tert-butyl-L-aspartate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine (23). 
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5’-N-(N-acetyl-3-azido-L-alaninyl-O-tert-butyl-L-aspartate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene 
uridine (24). 
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5’-N-(N-acetyl-3-azido-L-alaninyl-L-aspartate)-5’-amino-5’-deoxy uridine (25). 
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5’-N-(N-acetyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-alaninyl-O-tert-butyl-L-aspartate)-5’-
amino-5’-deoxy-2’,3’-O-isopropylidene uridine (37). 
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5’-N-(N-acetyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-alaninyl-L-aspartate)-5’-amino-5’-deoxy 
uridine (26). 
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5’-N-(N-myristoyl-3-azido-L-alaninyl-O-tert-butyl-L-aspartate)-5’-amino-5’-deoxy-2’,3’-O-isopropylidene 
uridine (27). 
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5’-N-(N-myristoyl-3-azido-L-alaninyl-L-aspartate)-5’-amino-5’-deoxy uridine (28). 
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5’-N-(N-myristoyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-alaninyl-O-tert-butyl-L-aspartate)-
5’-amino-5’-deoxy-2’,3’-O-isopropylidene uridine (38). 
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5’-N-(N-myristoyl-3-[4-(6-methoxynaphthyl)-1H-1,2,3-triazol-1-yl]-L-alaninyl-L-aspartate)-5’-amino-5’-
deoxy uridine (29). 
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